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SUMMARY 
In today’s ageing populations, the incidence of age-related neurodegenerative 
diseases is on the rise. More often than not, activated microglia are implicated 
in the pathogenesis of these diseases. It has been well established that 
CD137 ligand (CD137L) is expressed on antigen presenting cells (APCs) 
such as monocytes and macrophages. In line with this observation, our group 
had previously reported the expression of CD137L on microglia, the resident 
APC in the central nervous system (CNS), and its ability to induce microglia 
activation upon cross-linkage. Surprisingly, there has been very little research 
done on the consequences of CD137L reverse signalling into microglia. Given 
microglia’s status as the primary immune cell in the CNS, it is highly likely that 
CD137L-mediated microglia activation plays a significant role in 
neuroinflammation leading to the pathogenesis of CNS-related inflammatory 
disorders. In this study, we have identified CD137-expressing neurons as one 
of the potential interacting partners of CD137L-expressing microglia within the 
CNS. We have also demonstrated for the first time the upregulation of 
neuronal CD137 expression under pathological conditions. Aside from that, 
we unravelled several mechanisms mediating CD137L-mediated microglia 
activation. Firstly, CD137L-activated microglia is able to trigger neuronal 
apoptosis via reactive oxygen species (ROS) secretion. Secondly, microglia 
activated by CD137 reverse signalling induces the production of pro-
inflammatory factors and T cell proliferation in the presence of activated T 
cells, establishing a pro-inflammatory environment in the CNS. These data 
reveal the substantial role that CD137-CD137L interaction plays in mediating 
microglia involvement in the pathogenesis of neuroinflammatory diseases.    
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1 INTRODUCTION 
As the average life expectancy increases, coupled with declining early and 
mid-life mortality, as well as birth rate, a new population demographic trend is 
beginning to emerge: an ageing population. While technology and medical 
advances have drastically improved quality of life and prolonged lifespan, an 
ageing population comes with a different set of problems. These problems 
include disorders of the nervous system such as Alzheimer’s disease (AD) 
and Parkinson’s disease (PD).  
 
Neurological disorders such as AD and cerebrovascular diseases are often 
associated with ageing	   (Hung et al., 2010). Currently, there are about 18 
million individuals suffering from AD and the numbers are predicted to 
increase to a whopping 34 million by 2025	   (Cuny, 2012). On top of being 
more prone to these disorders, ageing individuals also have a diminished 
ability for recovery. This afflicts patients with long-term cognitive and 
functional impairments, rendering them to be dependable. For most 
neurological diseases, there are no known cures, and treatments are only 
available to enhance quality of life whilst living with the disease. Furthermore, 
these treatments have adverse effects and limited benefits	   (Green et al., 
2005; Kingwell et al., 2010; Muller, 2012).  
 
It has become more urgent than ever to continue research efforts in order to 
understand neurological disorders better in light of an ever-growing ageing 
population. Hence, this study aims to shed light on possible mechanisms that 
may have a role in the pathogenesis of neurological diseases. 
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1.1 The central nervous system (CNS) 
The central nervous system (CNS) is a vital constituent of the human body, 
responsible for the coordinating the functions of the body. Neurons are the 
basic unit of the CNS. Electrical and chemical signals are conveyed within the 
neurons intracellularly as well as between neurons intercellularly and this 
serves as a means of information transfer within the human body	   (Levitan & 
Kaczmarek, 2015).  
 
Neurons typically consist of a soma, an axon and dendrites. The soma of a 
neuron is essentially its cell body, which holds the nucleus. This is where 
most metabolic activities in a neuron occur. The axon is a delicate, tube-like 
protrusion extending out of the soma. It conducts electrical impulses termed 
action potential from the soma towards other neurons. Most axons have a 
myelin sheath around it to minimise loss of signal. The dendrites have similar 
functions to that of axons, which is to transmit action potentials. However, 
they carry impulses arising from inputs of other neurons towards the soma. 
Unlike axons, dendrites are usually shorter in length, more branched and 
unmyelinated	  (Eysenck, 2004).  
 
While neurons make up the major part of the CNS, there exists another 
population of cells within the CNS, called glial cells. Glial cells can be further 
subdivided into astrocytes, oligodendrocytes and microglia. Astrocytes have 
the function of maintaining the milieu in the CNS optimal for neuronal 
signalling. Oligodendrocytes, on the other hand, are responsible for laying 
down as well as maintaining myelin sheaths around neuronal axons. Myelin, a 
lipid-rich structure, is required for efficient conduction of action potentials 
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within neurons as it reduces the metabolic expense of signal transmission. 
Finally, microglia is the main component of the CNS intrinsic immune system, 
which will be discussed later in this thesis	  (Purves, 2004).  
 
The CNS is made up of two main components, mainly the brain and the 
spinal cord. Being a delicate system, the central nervous system is protected 
in several ways namely via the skeletal system, meninges, cerebrospinal fluid 
and the blood-brain barrier. Protection by the skeletal system comprises the 
skull and the vertebral column, which serve as an armour for the brain and 
the spinal cord respectively. Beneath them lie the meninges, which 
encompasses three layers of protective membranes: dura mater, arachnoid 
mater and pia mater (Johns, 2014). Both the skeletal system and the 
meninges largely serve as protection against mechanical injury. The 
cerebrospinal fluid (CSF), the third line of protection, fills the subarachnoid 
space between the arachnoid and pia mater. Not only does it act as a cushion 
against mechanical trauma, it also provides immunological protection to the 
CNS (Irani, 2009). Lastly, the blood-brain barrier (BBB), perhaps the most 
discussed CNS protection, is essentially a diffusion barrier that protects the 
CNS from chemical insult (Ballabh et al., 2004). It plays the crucial role in 
mediating the establishment of a stable microenvironment needed for reliable 
signalling of neurons (Abbott et al., 2010). 
 
1.1.1 Blood-brain barrier and CNS immune privilege 
The BBB is comprised of endothelial cells, the basement membrane, 
pericytes and the endfeets of astrocytes	   (Ballabh et al., 2004). For a long 
time, the CNS has been regarded as one of the immune privileged sites in the 
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human body due to the existence of the BBB. The BBB is selectively 
impermeable to certain cells, proteins and amino acids due to several 
properties. Firstly, the presence of tight junctions between endothelial cells of 
the BBB limits diffusion due to high electrical resistance. Secondly, these 
endothelial cells have relatively poor fluid-phase endocytic abilities and 
thereby, restricting transcellular inflow. Lastly, pericytes embedded within the 
BBB have efficient phagocytic capabilities	   (Mantegazza & Bernasconi, 2002). 
An efficient gatekeeper, the BBB is known to keep immune cells at bay, away 
from the delicate CNS parenchyma and hence, rendering the CNS protected 
from immune-mediated damage	  (Brady et al., 2012). 
  
However, accumulating evidence has begun to redefine this notion and 
suggested that there is a certain level of communication and interaction 
between the CNS and the peripheral immune system (Ransohoff et al., 2003). 
In fact, these interactions may be imperative to maintain the integrity of the 
CNS so that it is probably more appropriate to consider the CNS as an 
immune specialised site rather than an immune privileged site	   (Carson et al., 
2006). 
 
Nevertheless, in spite of this new insight, the BBB still holds a certain degree 
of restriction and limits the entry of leukocytes as well as macromolecules. It 
prevents unregulated leakage of compounds and substances into the CNS 
parenchyma that may have dire effects on neurons	   (Banks, 2015). These 
compounds and substances include platelets and their secretory products, 
proteases as well as albumin	   (Joseph et al., 1992; Nadal et al., 1995; 
Gingrich & Traynelis, 2000). This would mean that perturbation of the BBB 
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can bring about dire consequences and indeed, BBB impairment has been 
shown to associate with numerous CNS-related diseases including vascular 
dementia, multiple sclerosis and Alzheimer’s disease (Wallin et al., 1990; 
Minagar & Alexander, 2003; Sharma et al., 2012). Under pathological 
conditions, mediators altering the permeability of the BBB are secreted. 
These mediators include quinolinic acid, bradykinin and matrix 
metalloproteinases (St'astny et al., 2000; Pan et al., 2001; Rosenberg & 
Yang, 2007). It is for this reason that quantifying levels of specific proteins in 
the CSF serves as a method of diagnosing some CNS-related diseases such 
as stroke and Creutzfeldt-Jakob disease (Strand et al., 1984; Skinningsrud et 
al., 2008). 
 
Other than neurotoxic substances, the impairment of BBB integrity also allows 
the damaging of peripheral immune cells in the CNS parenchyma. Infiltration 
of immune cells such as activated T cells, dendritic cells and monocytes have 
been observed in CNS-related disorders	   (Zeine & Owens, 1992; Reichmann 
et al., 2002; Ajami et al., 2011). The infiltration of these leukocytes is aided by 
the upregulation of adhesion molecules on endothelial cells of the BBB such 
as VCAM-1 and ICAM-1	   (Larochelle et al., 2011; Martinez Gomez et al., 
2012). The initial wave of leukocyte infiltration then triggers subsequent 
migration of leukocytes into the CNS due to the secretion of chemotactic 
molecules as well as BBB-compromising mediators	  (Seguin et al., 2003). This 
gives rise to the accumulation of immune cells in the CNS, which may 
significantly alter the CNS milieu and thus, result in the deterioration of 
neuronal structure and signalling. 
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1.1.2 Microglia as the primary immune cell in the CNS 
In the CNS, microglia are the primary immune cells, making up approximately 
10-15% of the glia population	  (Brady et al., 2012). Microglia are considered to 
be the resident macrophages in the CNS, grouped together with peripheral 
tissue macrophages and monocyte-derived cells	   (Prinz & Priller, 2014). As 
with tissue macrophages in the periphery, microglia are also scavenging 
phagocytes, clearing cellular debris in the CNS parenchyma	   (Brady et al., 
2012). While they may be highly similar to peripheral macrophages, their 
myeloid lineages differ as microglia are not derived from the typical 
hematopoietic stem cells but from yolk sac-derived primitive macrophages. 
These primitive macrophages subsequently invade the developing CNS in the 
embryo and serve as embryonic source of the microglial population in the 
developing CNS	  (Ginhoux et al., 2013).  
 
Microglia can exist in two types in the adult CNS: ramified and reactive. The 
ramified form is usually associated with resting microglia. However, though 
ramified microglia are “resting”, they are extremely vigilant as surveillants in 
the CNS parenchyma	   (Nimmerjahn et al., 2005). These microglia are also 
referred as M0-polarised microglia	   (Prinz & Priller, 2014). They actively scan 
their surroundings for threats and mediate prompt responses to CNS insults. 
Microglia are able to detect minute changes via numerous surface receptors, 
including scavenger receptors, receptors for complement fragments, and 
immunoglobulins as well as toll-like receptors	   (Raivich et al., 1999; Trudler et 
al., 2010; Wilkinson & El Khoury, 2012). Resting microglia are characterised 
by their long branched processes, covering territories up to 40 μm in 
diameter, a huge advantage for their CNS surveillance function	  (Raivich et al., 
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1999). Resting microglia are evenly distributed in the CNS, and can be found 
in both the white and grey matters of the brain	   (Compston et al., 1997; 
Tremblay & Sierra, 2014). 
 
Upon detection of any threats or insults, resting microglia undergo rapid 
transformation into an activated state. This is where microglia assume their 
second form: the reactive form. Unlike the ramified version, reactive microglia 
exhibit larger cell bodies, reduced ramification as well as thickening of 
processes	   (Raivich et al., 1999). Reactive microglia are said to adopt 
characteristics of amoeboid microglia, a form of microglia that can only be 
found in a developing brain	   (Rock et al., 2004). Similar to that of 
macrophages, microglia are able to take on different states of polarisation. 
While there may be more polarisation states, the two most well-established 
states of reactive microglia are the M1 and M2 polarisations	   (Prinz & Priller, 
2014).  
 
In general, M1-polarised microglia are associated with pro-inflammatory 
responses while M2-polarised ones exhibit anti-inflammatory responses. 
Microglia in the M1 state, also referred as classically activated microglia, 
secrete high amounts of pro-inflammatory mediators as well as oxidative 
metabolites (Kobeissy, 2015). The pro-inflammatory factors produced include 
cytokines such as IL-1, IL-6, IL-12, IL-17, IL-23 and TNF-α as well as 
chemokines such as CCL2-5 and CXCL10 (Goldmann & Prinz, 2013; 
Orihuela et al., 2016). These mediators and metabolites are crucial for their 
defence activity and phagocytic functions. IL-12 promotes the differentiation 
of TH1 cells whereas IL-23 and IL-17 are essential for the TH17 cell 
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differentiation	  (El-Behi et al., 2011; Goldmann & Prinz, 2013).  The phagocytic 
ability of M1-polarised microglia is dependent on nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase. In fact, it plays a vital role in 
maintaining the microglia in its classically activated state. Choi et al. (2012) 
demonstrated that inhibition of NADPH oxidase has the ability to alter the 
polarisation state of microglia from M1 to alternatively activated M2 state 
under inflammatory conditions. 
 
M2-polarised microglia produce and release anti-inflammatory cytokines such 
as IL-4, IL-10 and TGF-β to facilitate the differentiation of protective T 
regulatory (Fletcher et al., 2010). These alternatively activated microglia has 
been shown to be involved in neuroprotection as well as neurogenesis and 
oligodendrogenesis	  (Hanisch & Kettenmann, 2007). 
 
Polarisation of microglia depends on the type of stimuli they receive from their 
surroundings. Cytokines like IFN-γ, IL-1β, IL-6 and TNF-α skew polarisation of 
microglia towards the M1 state	  (Goldmann & Prinz, 2013). On the other hand, 
the M2 polarisation state is assumed as a result of IL-4 and IL-13	   (Kobeissy, 
2015; Orihuela et al., 2016). Polarisation of microglia is not a terminal event 
and switching from one state to another is possible depending on the local 
milieu. The switching of states is not an instantaneous process, but instead, a 
slow transition between states over the course of 3 – 7 days. This suggests 
that there may be a mixture of M1-polarised and M2-polarised microglia under 
pathological conditions and the balance between these two populations of 
microglia may be critical in determining the detrimental or protective net 
contribution by microglia	  (Kofler & Wiley, 2011). 
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1.1.3 Microglia and neurodegeneration 
Neuroinflammation, more often than not, has been associated with activated 
microglia. In multiple sclerosis (MS), a hallmark of its pathogenesis is the 
accumulation of activated microglia found near or in CNS lesions. These 
reactive microglia have been shown to phagocytise oligodendrocytes and 
myelin debris. While phagocytosis of myelin debris is essential for 
remyelination to take place, the phagocytic activity of microglia also induces 
oxidative burst, resulting in the release of reactive oxygen species (ROS) 
(Goldmann & Prinz, 2013). The release of these oxidative metabolites is 
harmful to surrounding cells, inducing oxidative damage and eventually, 
death. Hence, neuronal death ensues, giving rise to another hallmark of MS: 
neurodegeneration.  
 
Microglia have also been implicated in the pathogenesis of AD. The disease 
is mainly characterised by the presence of neurofibrillary 
hyperphosphorylated tau tangles and extracellular fibrillar β-amyloid plaques	  
(Lau & Brodney, 2008). Reactive microglia have been found in amyloid 
plaques and were even hypothesised to secrete the amyloid protein	  
(Perlmutter et al., 1990; Lau & Brodney, 2008). Similar to MS, these reactive 
microglia release ROS and reactive nitrogen intermediates in the presence of 
fibrillar β-amyloid protein. Aside from that, activated microglia have been 
demonstrated to secrete elevated levels of pro-inflammatory cytokines and 
chemokines including IL-1β and TNF-α. This induces the establishment of an 
inflammatory CNS milieu as well as neuronal oxidative damage, giving rise to 
the neurodegenerative pathology of AD	  (Wilkinson & Landreth, 2006). 
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PD is one of the most prevalent neurodegenerative diseases after AD	   (Hung 
et al., 2010). The disease is characterised by a substantial loss of 
dopaminergic neurons found in the substantia nigra as well as eosinophillic 
Lewy inclusion bodies	   (Prinz et al., 2011). Aside from that, reactive microglia 
have been found to accumulate in the substantia nigra in Parkinson’s disease 
brains (McGeer et al., 1988). Lewy bodies are formed in neurons due to the 
accumulation of misfolded α-synuclein proteins. These aggregated Lewy 
bodies may be secreted into the substantia nigra, resulting in the activation of 
microglia. Production of ROS and pro-inflammatory factors by activated 
microglia then ensues, enhancing α-synuclein-mediated neurodegeneration 
(Zhang, Wang, et al., 2005).  
 
1.2  CD137-CD137 ligand (CD137L) signalling system 
1.2.1 CD137 
CD137, also recognized as TNFRSF9 or 4-1BB, is a member of the tumour 
necrosis factor (TNF) receptor superfamily (Schwarz et al., 1997). A potent 
co-stimulatory molecule, it is mainly expressed on activated T cells. CD137 
on T cells is involved in activation, proliferation, cytokine secretion and 
enhanced cytolytic effector function (Wen et al., 2002).  Other than on T cells, 
CD137 can also be found on other types of cells including natural killer (NK) 
cells, dendritic cells (DCs) and inflamed endothelial cells (Melero et al., 1998; 
Broll et al., 2001; Futagawa et al., 2002). The expression is dependent on 
activation, giving CD137 its other name, induced by lymphocyte activation 
(ILA)	  (Schwarz et al., 1995). 
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Human CD137 is encoded on chromosome 1p36 while the gene for murine 
CD137, is found on chromosome 4 (Schwarz et al., 1997). Human and murine 
CD137 share a 60% similarity at the amino acid level (Alderson et al., 1994). 
Expression of murine CD137 messenger ribonucleic acid (mRNA) is induced 
about 3 hours after cell stimulation. Optimal CD137 expression then ensues 
after 60 hours. As for human CD137, its mRNA is detectable after only 1.5 
hours in T cells. It then reaches its maximum expression after 8 hours 
followed by a decline, reaching basal levels after 48 hours (Orentas et al., 
2008). 
 
There are two forms of CD137 protein, mainly membrane-bound and soluble 
form. CD137 can exist as a 30-kDa monomer and a 55-kDa dimer (Pollok et 
al., 1993). Human soluble CD137 has a molecular weight of 16-kDa, 
generated from mRNA spliced differently to result in a protein without a 
transmembrane region (Michel et al., 1998). In mice, the soluble form of 
CD137 is the result of an alternatively spliced mRNA variant, which lacks the 
transmembrane domain (Setareh et al., 1995). Secretion of soluble CD137 is 
restricted to activated lymphocytes. Soluble CD137 has been shown to act 
antagonistically to CD137 signalling, thus providing a negative feedback on 
occurring inflammation (Michel et al., 1998; Kim et al., 2011). 
 
1.2.2 CD137L 
CD137L, the binding partner to CD137, is a transmembrane molecule 
expressed by APCs. Also recognised as 4-1BB ligand (4-1BBL), it is part of 
the TNF superfamily (Goodwin et al., 1993). In the murine system, the gene 
encoding CD137L is located at chromosome 17	   (Orentas et al., 2008). 
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Constitutive murine CD137L expression can be found on macrophages, B 
cells and stromal cells of the thymus and bone marrow	   (Langstein et al., 
1998). Human CD137L, mapped to chromosome 19, is constitutively 
expressed by monocytes and B cells (Langstein et al., 1998; Orentas et al., 
2008). The human and murine CD137L are 36% homologous (Alderson et al., 
1994). Similar to CD137, CD137L can also exist in two forms, as a 
transmembrane molecule as well as a soluble protein	  (Salih et al., 2001).  
 
1.2.3 Bidirectional signalling of CD137-CD137L interaction 
CD137 interacts with CD137L to give a disulfide-linked dimer (Goodwin et al., 
1993). Upon CD137 ligation with CD137L, a bidirectional signalling is induced 
into the cells bearing the receptor or ligand. This phenomenon is observed 
with other members of the TNF family such as CD30, CD40 and OX40 
(Langstein et al., 1998). This gives rise to a whole plethora of immune 
responses as a result of the bidirectional signalling between CD137 and 
CD137L. 
 
CD137 signal into T cells have shown to be involved in effective anti-tumour 
response by stimulation of CD8+ cytotoxic T lymphocyte response and 
enhanced IFN-γ production (Melero et al., 1997). DCs of CD137-/- mice have 
poor survival rate as well as compromised antigen presentation, indicating the 
importance of CD137 for proper DC functioning	  (Choi et al., 2009). Aside from 
that, CD137 ligation on endothelial cells increases expression of cell surface 
adhesion molecules to augment leukocyte migration into tumours or inflamed 
tissues	  (Drenkard et al., 2007; Palazon et al., 2011). 
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In monocytes, cross-linking of CD137L results in monocytic activation, 
enhanced adherence and increases secretion of pro-inflammatory cytokines 
such as IL-6, IL-8 and TNF-α (Langstein et al., 1998). Besides that, CD137L 
reverse signalling into DCs has been reported to aid in cell maturation in an 
autocrine or paracrine manner via TNF-α production and it facilitates cell 
migration by upregulating CCR7 chemokine receptor expression. These DCs 
skew differentiation of T cells towards a TH1 effector profile	   (Lippert et al., 
2008). 
 
1.3 Research objectives 
Recently, expression of CD137L has been reported on microglia and that 
CD137 reverse signalling into microglia is capable of triggering its activation	  
(Yeo et al., 2012). In light of the significant role microglia play in the 
pathogenesis of numerous neurodegenerative diseases, one could not help 
but to wonder: Is it possible for CD137-CD137L signalling system to be 
involved in microglia-mediated immune responses contributing to the 
pathogenesis of CNS-related disorders? If so, what are the CD137-
expressing cells that could potentially interact and trigger CD137L-mediated 
microglia activation? 
 
Hence, this study seeks to fulfil the objectives stated below: 
1. To identify CD137-expressing CNS resident cell(s) if any. 
2. To uncover potential effects of CD137L-mediated microglia activation 
in the context of neurodegeneration. 
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2 MATERIALS AND METHODS 
2.1 Western blot 
Tissues lysates for murine cerebellar granule neurons, cortex, hippocampus 
and forebrain were kindly given by Professor Carlos Ibanez (Department of 
Physiology, NUS). Associate Professor Thiruma Arumugam (Department of 
Physiology, NUS) generously provided murine contralateral and ipsilateral 
hemispheric tissues. Murine cerebellum, pons and medulla tissues were 
obtained from C57BL/6 mice that have been transcardially perfused with 1× 
phosphate-buffered solution (PBS).  
 
These tissues were homogenised and lysed using radioimmunoprecipitation 
assay buffer (RIPA buffer) or T-PER™ Tissue Protein Extraction Reagent 
(Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 
phosphatase and protease inhibitors. Lysates were resuspended in 5× 
Laemmli sample buffer and boiled for 5 minutes at 95°C. The resulting protein 
samples were then resolved using 12% SDS-PAGE gels and transferred onto 
polyvinylidene difluoride (PVDF) membranes (Merck Millipore, Billerica, MA 
USA). CD137 and actin proteins were detected by goat anti-murine CD137 
(R&D Systems, Minneapolis, MN, USA) and goat anti-actin (Santa Cruz 
Biotechnology, Dallas, TX, USA). The unconjugated primary antibodies were 
then detected with HRP-conjugated anti-goat IgG secondary antibody (Santa 
Cruz Biotechnology) and visualised using ultra-sensitive enhanced 
chemiluminescent substrate (Thermo Fisher Scientific).  
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2.2 Tissue immunofluorescence  
Brain tissues of wild-type (WT) and DMT-1 mice, a kind gift from Professor 
Soong Tuck Wah (Department of Physiology, NUS), were previously 
embedded in paraffin and sectioned to a thickness of 4.5 μm. Sectioned 
tissues were deparaffinised in Richard-Allan Scientific Clear-Rite™ 3 (Thermo 
Fisher Scientific) and hydration was done in graded series of ethanol. Antigen 
retrieval was done for 30 minutes at 37°C in prewarmed 20 μg/ml Proteinase 
K (Sigma-Aldrich, St. Louis, MO, USA). Endogenous biotin in tissues were 
then blocked using avidin/biotin blocking kit (Thermo Fisher Scientific) 
according to manufacturer’s protocol before blocking tissues with 2% goat 
serum and 1% BSA in 1× PBS with 0.05% Tween 20 (1× PBST). After 
blocking is completed, tissue sections were incubated with primary antibody 
overnight at room temperature, followed by secondary antibody incubation for 
1 hour at room temperature. Sections are then counterstained with 4’,6-
diamidino-2-phenylindole (DAPI) for 15 minutes at 37°C. Slides were mounted 
using FluorSave™ Reagent (Merck Millipore). Tissues sections were viewed 
and documented using Zeiss AxioImager Z1 (Zeiss, Oberkochen, Germany). 
Image analysis was done on Zeiss AxioVision software. 
 
Biotinylated goat anti-murine CD137 (R&D Systems), rabbit anti-calbindin-
D23k (Swant, Marly, Switzerland) and rabbit anti-β-tubulin III (Abcam, 
Cambridge, UK) antibodies were used to detect murine CD137, calbindin-
D23k and β-tubulin III respectively. The bound unconjugated antibodies were 
detected using APC-conjugated streptavidin (eBioscience, San Diego, CA, 
USA) and Alexa Fluor® 488-conjugated anti-rabbit IgG antibody (Invitrogen, 
Carlsbad, CA, USA). 
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2.3 Frozen tissue immunofluorescence and immunohistochemistry  
Frozen murine brain tissues from sham and stroke-induced mice were 
generously provided by Professor Thiruma Arumugam. Tissue sections were 
first rinsed in 1× PBS before permeabilisation in 0.2% Triton-X in 1× PBS for 
5 minutes at room temperature was carried out. The sections were then 
blocked for an hour at room temperature with 1% BSA in 1× PBS. After 
washing the sections twice with 1× PBST, sections were incubated with 
primary antibodies overnight at 4°C. Incubation with secondary antibody was 
then done for 1 hour at room temperature.  
 
For immunofluorescence, nuclei were counterstained with DAPI for 10 
minutes at room temperature before the tissues were mounted with 
FluorSave™ Reagent. Immunofluorescence was visualised and analysed as 
mentioned above in Section 2.2. For immunohistochemistry, DAB substrate 
was employed to visualise bound unconjugated secondary antibody before 
counterstaining with haematoxylin (Sigma-Aldrich). Haematoxylin-stained 
tissues were then mounted using DPX mountant (Sigma-Aldrich). Stained 
tissues were visualised using Leica DM2000 microscope and imaged using 
Leica Application Suite. 
 
Monoclonal rat anti-murine CD137 antibody (Clone 3H3), a generous gift from 
Dr. Mark Smyth (University of Melbourne, Australia), and DyLight™ 649 anti-
rat IgG antibody (BioLegend, San Diego, CA, USA) was utilized for the 
detection of CD137 via immunofluorescence. As for immunohistochemistry, 
the antibodies used were biotinylated 3H3 clone and HRP-conjugated 
streptavidin (Sigma-Aldrich). 
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2.4 Primary cells  
2.4.1 Primary neurons and astrocytes 
Primary neurons isolated from cortex of murine pups were generously 
provided by Associate Professor Thiruma Arumugam. Cells were maintained 
in Neurobasal® medium (Life Technologies, Carlsbad, CA, USA) at 37°C, 5% 
carbon dioxide (CO2) for 10 days before they were used for experiments. 
 
Primary human astrocytes were procured from Life Technologies. The cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) High Glucose 
(Serana, Bunbury, WA, Australia) culture medium containing 10% heat-
inactivated fetal bovine serum (FBS) (Biowest, Nuaillé, France) and 1% N-2 
supplement (Life Technologies).  Culture conditions were similar as the 
above. 	  
2.4.2 Isolation of murine CNS cells 
C57BL/6 mice were transcardially perfused before the brain was extracted. 
Brain tissues were meshed using a 70 μm cell strainer and flushed with 2 mM 
EDTA in 1× PBS.  Cells were then resuspended in Roswell Park Memorial 
Institute Medium (RPMI-1640) (Serana) with 10% heat-inactivated fetal 
bovine serum (R10), supplemented with Penicillin-Streptomycin (Biowest).  
Cultures were incubated at 37°C in 5% CO2.  
 
2.4.3 Isolation of murine T cells 
Mice were sacrificed via CO2 overdose by inhalation. Spleens were then 
extracted, mechanically meshed and passed through 70 μm cell strainers. T 
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cells were then isolated using the EasySep™ Mouse T Cell Isolation Kit 
(Stemcell Technologies, Vancouver, Canada) according to manufacturer’s 
protocol. Cells were then resuspended in R10 supplemented with Penicillin-
Streptomycin and maintained at 37°C under 5% CO2 condition. 
 
2.4.4 Human embryonic stem cells–derived dopaminergic neurons 
Human embryonic stem cells (hESC)-derived dopaminergic neurons were 
generously gifted by Associate Professor Cao Tong (Faculty of Dentistry, 
NUS). Cells were maintained in Neurobasal® medium (Life Technologies) 
supplemented with 1× non-essential amino acid (NEAA) (Sigma-Aldrich), 1× 
GlutaMAX™ (Life Technologies) and B-27 supplement (Life Technologies) at 
37°C, 5% CO2. 
 
2.4.5 Isolation of human T cells 
Peripheral blood mononuclear cells (PBMCs) were obtained after gradient 
centrifugation of buffy coat using Ficoll-Paque PLUS (GE Healthcare, 
Buckinghamshire, UK). Human T cells were then isolated using EasySep™ 
Human T cell Isolation Kit (Stemcell Technologies) according to 
manufacturer’s protocol. T cells were then resuspended in R10 supplemented 
with Penicillin-Streptomycin. 
 
2.5 Cell lines and cell culture 
Neuro-2a is an albino murine neuroblastoma cell line. It was a kind 
contribution from Professor Wong Boon Seng (Department of Physiology, 
NUS). The cells are cultured in DMEM High Glucose (Serana) culture medium 
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containing 10% heat-inactivated FBS and 1 mM sodium pyruvate (Sigma-
Aldrich). Neuro-2a was subsequently transfected to express murine CD137 
and henceforth referred to as N2aT/muCD137. Its control, N2aT/pcDNA3.0, 
was transfected with an empty vector. Transfected cells were maintained in 
the same media with additional 100 μg/ml of Geneticin® (Life Technologies). 
Murine microglia cell line BV-2 was procured from Biological Bank and Cell 
Factory IRCCS (Banca Biologica e Cell Factory, Genova, Italy). N9, another 
mouse microglia cell line, was generously gifted by Dr. Wong Siew Heng 
(Department of Microbiology, NUS). Both microglia cell lines were maintained 
in R10 media.  
 
CRL1718, provided kindly by Professor Kandiah Jeyaseelan (Department of 
Biochemistry, NUS), is a human grade IV astrocytoma cell line. U373-MG 
human glioblastoma cells were given benevolently by Dr. Celestial Yap 
(Department of Physiology, NUS). U937 human monocytic cell line was 
obtained from American Type Culture Collection (ATCC, Manassas, VA, 
USA). These 3 abovementioned cell lines were cultured in R10 medium. 
 
All cell lines were grown at 37°C in 5% CO2. Media was replaced every 2 to 4 
days until confluence was attained. 
 
2.6 Reagents 
Calcium ionophore (A23187), catalase, concanavalin A (Con A), 
cycloheximide, lipopolysaccharide (LPS) from E. coli (serotype 0111:B4), 
phorbol 12-myristate 13-acetate (PMA) and prostaglandin E2 (PGE2) were 
obtained from Sigma-Aldrich.  
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Murine GM-CSF, IFN-γ, IL-1β	  and TNF as well as human IL-1β, IL-10, TGF-β 
and TNF were purchased from PeproTech (Rocky Hill, NJ, USA). Murine 
basic FGF, human basic FGF were procured from BioLegend while NGF-β 
was from R&D systems. Poly I:C was obtained from InvivoGen (San Diego, 
CA, USA) and retinoic acid (RA) was acquired from Abcam.  
 
Anti-human CD137 antibody P2F2 and anti-human CD137L antibodies P1A7, 
P1G1 and P2D5 are kindly provided by Dr. Wang Cheng-I (Singapore 
Immunology Network, Singapore). Anti-human CD137L antibodies clone C65-
485, clone 41B436 and clone 5F4 were purchased from BD Pharmingen (BD 
Biosciences, San Jose, CA, USA), Alexis Biochemicals (Enzo Life Sciences, 
Farmingdale, NY, USA) and BioLegend respectively. Isotypes for these above 
antibodies, human IgG antibody and murine IgG1 antibody clone MOPC 21 
were procured from Sigma-Aldrich. 
 
2.7 Flow cytometry 
2.7.1 Extracellular staining 
Prior to staining, cells were washed at least once with fluorescence-activated 
cell sorting (FACS) buffer. For cells of human origin, blocking with human FcR 
blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) was first 
done at 1:25 dilution for 10 minutes at 4°C. Subsequently, cells are stained 
with labelled or unconjugated antibodies for 15 minutes at room temperature 
or 30 minutes at 4°C. For samples with unconjugated antibodies, cells were 
washed with FACS buffer before incubation with conjugated secondary 
antibodies was done under conditions similar to primary antibody incubation. 
Stained cells are then resuspended in FACS buffer. Non-specific staining was 
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taken into account using isotype control antibodies. Flow cytometry was done 
using CyAn™ ADP Analyzer (Beckman Coulter, Brea, CA, USA) or BD 
LSRFortessa™ (BD Biosciences) and analysed using Summit software 
(Dako, Glostrup, Denmark) or FlowJo software (FlowJo, Ashland, OR, USA). 
Table 1 shows the list of antibodies used for flow cytometry.  	  
2.7.2 Intracellular staining 
Extracellular staining was done before cells were prepared for intracellular 
staining. Intracellular staining was employed for the detection of RORγt using 
PE-conjugated anti-human/mouse RORγt antibody (eBioscience) according to 
manufacturer’s protocol. CyAn™ ADP Analyzer (Beckman Coulter) was used 
to quantify the fluorescence and data was analysed using Summit software 
(Dako). 
 
Table 1. List of antibodies utilised 
Antigen* Host Conjugate Clone Vendor 
β-tubulin III (m) rabbit unconjugated - Abcam 
β-tubulin III (h) mouse unconjugated TU-20 Abcam 
CD137 (m) hamster PE 17B5 BioLegend 
CD137 (h) mouse PE 4B4-1 BD Pharmingen 
CD137L (m) rat PE TKS-1 BioLegend 
CD137L (h) mouse PE 5F4 BioLegend 
CD3 (m) rat APC-eFluor® 780 17A2 eBioscience 
CD45 (m) rat FITC 30-F11 eBioscience 
MAP-2 (m/h) rabbit unconjugated - Sigma-Aldrich 
*(m) depicts for murine antigen and (h) depicts for human antigen. 
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2.8 Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde at room temperature for 15 
minutes. Permeabilisation was done using 0.2% Triton-X in 1× PBS at room 
temperature for 5 minutes. The cells were subsequently blocked with 1% BSA 
in 1× PBS for an hour at room temperature. After the blocking step is 
completed, cells were rinsed with 1× PBST twice before overnight incubation 
with primary antibody was done at 4°C. Cells were then incubated with 
secondary antibody for 1 hour at room temperature. Counterstaining with 
DAPI was done for 10 minutes at room temperature. FluorSave™ Reagent 
was used for mounting of cells. Immunofluorescence was visualised and 
analysed as mentioned above in Section 2.2. 
 
The same 3H3 clone and its corresponding secondary antibody mentioned in 
Section 2.3 were employed for the detection of murine CD137. For staining of 
human CD137, the primary antibody used was unconjugated rat monoclonal 
anti-human CD137 antibody (Clone JG1.6A) (Novus Biologicals, Littleton, CO, 
USA) with DyLight™ 649 anti-rat IgG antibody (BioLegend) as secondary 
antibody.  
 
2.9 Reverse transcription polymerase chain reaction (RT-PCR) 
2.9.1 Total RNA isolation 
Total RNA from cultured primary cortical neurons was extracted using 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s 
protocol. Briefly, 600 μl of RLT buffer provided was added to cells for lysis. 
Lysate was then homogenised using a 21-gauge needle. 600 μl of 70% 
ethanol was added to the homogenate and mixed well. Mixture was passed 
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through the RNeasy spin column by centrifuging at 13, 200 rpm for 15 
seconds. On-column DNase digestion was then done using RNase-free 
DNase set and RW1 buffer provided. RNeasy spin column was washed twice 
with RPE buffer provided before RNA was eluted using 30 μl of RNase-free 
water. RNA concentration was determined using ND-1000 spectrophotometer 
(Thermo Scientific).  	  
2.9.2 Reverse transcription 
500 ng of total RNA isolated was aliquoted into a PCR tube and RNase-free 
water was used to top up the volume of RNA to 13 μl. 1 μl of 10 mM dNTP 
and 1 μl of 0.2 mg/ml random hexamer primers were added. The mixture was 
heated at 65°C for 5 minutes and quick chill was then immediately done on 
ice. 4 μl of M-MLV buffer (Promega, Madison, WI, USA) was added into the 
mixture before heating the mixture at 25°C for 2 minutes 5 seconds. Finally, 1 
μl of 200 units/μl M-MLV reverse transcriptase was added. Reverse 
transcription was then done at 25°C for 10 minutes, 3 cycles of 10-minute 
intervals at 42°C and ended with a 15-minute interval at 70°C. The cDNA 
product resulted was kept at 4°C or -20°C. 	  
2.9.3 PCR 
Components of PCR mix and primers used are listed in Tables 2 and 3 
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Table 2. PCR mix per reaction 
Component Stock concentration 
Final 
concentration 
Volume of stock 
(μl) 
cDNA template - - 2 
Forward primer 100 μM 0.8 μM 0.2 
Reverse primer 100 μM 0.8 μM 0.2 
Taq buffer 10× 1× 2.5 
Taq polymerase 5 units/μl 0.025 units/μl 0.125 
dNTP mix 10 mM 0.2 mM 0.5 
Magnesium chloride  25 mM 2.5 mM 2.5 
Water - - Top up to 25 μl 
 
Table 3. Primers used for CD137 mRNA detection 
Primers Sequences (5’ – 3’) 
muCD137 FP1 ATG GGA AAC AAC TGT TAC AAC G 
muCD137 RP1 ACA GAA ATG GTG GTA CTG GGA G 
muCD137 FP2 TCT TCA CCT TTG GTG TCC TGT G 
muCD137 RP2 CGT TGT GGG TAG AGG AGC AA 
 
Table 4. PCR cycling conditions 
Steps Temperature (°C) 
Time 
(minutes) 
Initialisation 50 2 
Initial denaturation 95 3 
3-step cycling 
(30 cycles) 
Denaturation 95 0.25  (15 s) 
Annealing 65 0.5  (30 s) 
Extension 72 0.75 (45 s) 
Final extension 72 10 	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PCR products were then resolved on 2% agarose gels. Visualisation of DNA 
bands was done using GelGreen™ and UV transilluminator (Vilber Lourmat, 
Marne La Vallée, France). 	  
2.10 Induction of CD137 signalling in murine system 
24-well culture plates were coated with 10 μg/ml of either rat isotype IgG2a 
(eBioscience), 3H3 or anti-murine CD137 antibody clone 158332 (R&D 
Systems) overnight at 4°C. The wells were then washed twice and seeded 
with 0.25 × 106 N2aT cells per well in 500 μl of media. Cells were incubated 
for 24 hours at 37°C, 5% CO2. 	  
2.11 Annexin V and 7-AAD apoptosis assay 
Cells were stained with Alexa Fluor 647®-conjugated Annexin V (BioLegend) 
and 7-amino-actinomysin D (7-AAD) (BD Pharmingen) according to protocol 
provided by BD Pharmingen. Analysis was done on CyAn™ ADP Analyser 
using the APC and PE-Cy5 channels respectively. 	  
2.12 Measurement of cytokines via enzyme-linked immunosorbent 
assay (ELISA) 
Supernatants from cultures were collected and stored in -20°C until needed. 
Production of murine GM-CSF, IFN-γ, MCP-1, M-CSF, TNF as well as human 
GM-CSF and IL-17A were quantified according to manufacturers’ protocols. 	  
2.13 Light microscopy 
Morphological cellular changes were documented using Axiovert 40 inverted 
microscope (Zeiss) and Canon PowerShot G6 digital camera. 	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2.14 Statistical analysis 
Data are represented as means ± standard deviation of indicated figures. 
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3 RESULTS 	  
Being the primary immune cell population in the CNS, microglia have often 
been implicated in numerous CNS inflammation-related diseases such as 
multiple sclerosis, Parkinson’s disease and Alzheimer’s disease	  (Lull & Block, 
2010). More often than not, microglia activation is a hallmark of brain 
pathology (Dheen et al., 2007). Recently, Yeo et al. (2012) found that CD137L 
reverse signalling activates microglia, leading to the establishment of an 
inflammatory microenvironment. However, the cells involved in this CD137L 
reverse signalling induction have yet to be established. Hence, we seek to 
uncover both CNS-resident and external sources of CD137, which may be 
implicated in activation of CD137L-expressing microglia. 
 
3.1 Expression of murine CD137 in CNS 
CD137 has been detected mainly on lymphocytes such as activated T cells, 
dendritic cells and NK cells (Melero et al., 1998; Wilcox et al., 2002). 
However, CD137 has also been found on non-immune cells such as inflamed 
endothelial cells as well as vascular smooth muscle cells (Broll et al., 2001). 
In 2002, Sharief (2002) reported high levels of soluble CD137 (sCD137) in the 
CSF of patients with MS. Since the brain is an immune-privileged organ, it 
begets the question: what is the source of sCD137 in the CSF of patients? 
Could CNS-resident cells express it? Furthermore, previous studies from our 
group showed some evidence of CD137 expression in murine CNS tissues. 











































































































3.1.1 Murine CD137 expression is undetectable in various regions of 
the CNS 
With this in mind, we tested murine brain lysates for CD137 protein via 
Western blot. Unfortunately, we were unable to detect murine CD137 protein 
in the cerebellar neurons, cortex, hippocampus, forebrain, cerebellum, pons 
















Figure 1. Expression of CD137 protein is undetectable in different murine 
brain components. (a) Tissue lysates from cultured cerebellar granule neurons, 
cortex, hippocampus and forebrain were obtained from WT murine pups. (b) 
Cerebellum, pons and medulla were isolated from WT and CD137 knockout (KO) 
mice and lysed to obtain lysates. The protein expression levels were subsequently 
determined by Western blot analysis. Neuro-2a transfected with empty vector 
(N2aT/pcDNA3.0) and CD137-expressing Neuro-2a (N2aT/muCD137) were 
included as negative and positive controls for CD137 respectively. Actin was used 
as a loading control. 25 μg and 100 μg of protein were loaded into each well for 
controls and tissue lysates respectively. 	



















3.1.2 Expression of CD137 on murine neuronal cells 
As CD137 was undetectable via Western blot, we attempted detecting CD137 
protein using the more sensitive method of immunofluorescence. This was 
achieved by staining tissue sections of WT mice with anti-CD137 antibody 
and DAPI. CD137 was found on cells lining the grey matter of the cerebellum 
(not shown). Additional staining with anti-calbindin-D28k antibody, a Purkinje 
cell marker, confirmed CD137 expression on Purkinje cells (Figure 2), 











3.2 CD137 protein expression levels in diseased murine CNS tissues 
Elevated levels of sCD137 have been detected in patients with various 
diseases such as MS, rheumatoid arthritis and Crohn’s disease (Sharief, 
2002; Jung et al., 2004; Maerten et al., 2004). Furthermore, Olofsson et al. 
Figure 2. CD137 protein expression was detected on Purkinje cells. WT 
murine cerebellum tissue sections were stained for CD137 (red) and Purkinje 
neuronal cell marker, calbindin (green). Nuclei were counterstained with DAPI 
(blue). Colocalisation of CD137 and calbindin staining (yellow) indicates CD137-
expressing Purkinje cells. The white scale bar represents 20 μm.  
  	  








































































(2008) associated atherosclerosis and stroke with increased CD137 levels. In 
order to examine if this holds true for CD137 expression in the brain, we first 
stained brain tissues of stroke-induced mice and their sham counterparts for 
CD137 expression. Unfortunately, CD137 was not detectable in these tissues 
(Figure 3).  
 












Figure 3. Expression of CD137 protein is undetectable in brains of WT 
(Sham) and stroke-induced mice after 24-hour ischaemia/reperfusion (I/R).  
(a) Murine striatal tissue sections were stained for CD137 (red) and nuclei were 
counterstained with DAPI (blue). The white scale bar represents 20 μm. (b) 
Immunohistochemistry was performed on frozen murine brain tissues from WT 
and stroke-induced mice for CD137 (brown). The black scale bar represents 20 
μm. (c) CD137 western blot analysis in contralateral (Contra) and ipsilateral (Ipsi) 
hemispheres after 24 hour I/R. N2aT/pcDNA3.0 and N2aT/muCD137 were 
included as negative and positive controls for CD137 respectively. Actin was used 
as a loading control. 25 μg and 100 μg of protein were loaded into each well for 
controls and tissue lysates respectively. 
  	  


























We also stained CNS tissues of mice with overexpression of DMT-1, a model 
for Parkinson’s disease. Interestingly, higher expression of CD137 was 
observed in CNS tissues of mice with DMT-1 overexpression as compared to 
their WT counterparts (Figure 4a). This increase in CD137 expression was 
seen on neurons. While the percentage of neurons expressing CD137 
remains similar, intensity and area of CD137 expression are higher in mice 
with DMT-1 overexpression (Figure 4b – d). This insinuates that CD137 
expression in the CNS is elevated under diseased conditions.  
 
The above-described in vivo findings form the basis to study expression of 












































































































































3.3 Treatment of primary murine cells for CD137 expression 
Before experiments were carried out under in vitro settings, we first needed to 
obtain primary CNS cells that express CD137. While preliminary results 
showed that CD137 in CNS is expressed by neurons, it was still imperative to 
ensure that other resident CNS cells were not overlooked. Cells from brains of 
Figure 4. Higher expression of neuronal CD137 was seen in mice with DMT-
1 overexpression as compared to its WT counterpart. (a) Murine striatal tissue 
sections were stained for CD137 (red) and neuronal marker, β-tubulin III (green). 
Nuclei were counterstained with DAPI (blue). The white scale bar represents 20 
μm. (b) Percentages of CD137-expressing neurons in murine WT and DMT-1 
brains were evaluated from three fields each of three sections using Metamorph 
NX Software. (c) Average relative intensity of neuronal CD137 with isotype as the 
reference intensity and (d) average area of neuronal CD137 using Metamorph NX 
Software were depicted in means ± standard deviations (*p < 0.05, **p < 0.01). 
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WT, CD137 receptor knockout (CD137 RKO) and CD137 ligand knockout 
(CD137 LKO) mice were isolated and stained for CD137. It was found that 
CD137 was undetectable on untreated primary CNS cells (Figure 5). We 
followed up by treating the isolated CNS cells with various stimuli to induce 
CD137 expression. The CNS cells were stimulated with LPS, PMA and Poly 
I:C for 24 hours before staining the cells for CD137. CD137 staining was then 
quantified via flow cytometry. For WT, CD137 RKO and CD137 LKO CNS 
cells, CD137 expression remained unobserved despite the various treatments 
(Figure 5).  
 
As CD137 was not inducible on primary murine CNS cells, the focus was 
shifted to inducing CD137 on primary murine neurons. While there seemed to 
be no reports of CD137 expression on murine neurons, CD137 expression 
has been recently identified on neural stem cells derived from mouse 
embryonic cerebellum (Yun et al., 2013). This, in tandem with our 
abovementioned finding of CD137 expression on Purkinje cells, provided a 
basis to induce CD137 on primary murine neurons. 
 
As previous attempts of CD137 protein detection on cells have been futile, we 
decided to first determine if there was any CD137 mRNA expression in these 
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Figure 5. CD137 protein is not detected on murine central nervous system 
(CNS) cells upon treatment. CNS cells were isolated from (a) WT (b) CD137 
receptor knockout and (c) CD137 ligand knockout, and were left untreated or were 
treated with LPS, PMA or poly I:C for 24 hours. Cells were then stained with PE-
conjugated anti-murine CD137. Stained cells were analysed via flow cytometry. 
Percentages of CD137-positive cells are reflected in each graph. Open 
histograms are for isotype control and filled grey histograms are for CD137 
stained cells. 
  	  











































Primary murine cortical neurons were isolated from pups and cultured for 10 
days prior to treatment for up to 7 days. Treatments include PMA, calcium 
ionophore (A23187), RA, Con A and basic FGF. Indeed, we detected CD137 








With the establishment of CD137 mRNA expression in these cells, we then 
proceeded to investigate the protein expression of CD137 in primary murine 
neurons. The cells were treated with various reagents such as cycloheximide, 
LPS, PMA and RA or various cytokines such as GM-CSF, IL-1β, TNF and 
IFN-γ for 24 hours. The treated cells were then stained for CD137. For most 
treatments, CD137 was not induced on the primary murine cells (Figure 7). 
However, there seems to be a slight induction of CD137 protein expression 
on cells treated with PMA and RA as seen from the faint staining for CD137 
(Figure 7a). This indicates that PMA and RA may potentially be stimuli for 
CD137 induction in neurons.  
Figure 6. CD137 mRNA expression was detectable in primary murine 
neurons. Primary cortical neurons were isolated from pups and cultured for 10 
days before treatment. Cells were then treated for up to 7 days with PMA (30 
ng/ml), calcium ionomycin A23187 (0.1 μM), RA (20 μM), Con A (5 μg/ml) or 
basic FGF (25 ng/ml). Total RNA was isolated from the treated cells and reverse 
transcribed using M-MLV reverse transcriptase (Promega), followed by CD137 
cDNA amplification using Taq DNA polymerase (Thermo Scientific). The PCR 
products were then resolved on 2% agarose gel and visualise by GelGreen™ 
staining.  
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Figure 7. Expression of CD137 protein is not inducible in primary murine 
neurons despite various treatments. Primary cortical neurons were isolated 
from pups and cultured for 10 days before treatment. Cells were then treated for 
24 hours with (a) various reagents or (b) cytokines. Immunocytochemistry staining 
was performed on treated cells with anti-murine CD137 antibody and DyLight 649-
conjugated anti-rat IgG secondary antibody. The white scale bar represents 20 
μm.  
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3.4 Reduced CD137 expression on Neuro-2a cells upon differentiation 
It has been revealed that the differentiation status of the cells plays a role in 
the induction of CD137 expression on that particular cell (Kempis et al., 
1997). We hypothesised that the slight induction of CD137 by PMA and RA 
may be due to the differentiation status of the primary murine neurons. 
Whether expression of CD137 increases or decreases upon further 
differentiation still remained to be investigated.  
 
In order to examine this, we used 3 types of Neuro-2a cells: parental Neuro-
2a (N2a parental), N2aT/pcDNA3.0 and N2aT/muCD137. These cells were 
treated with 20 μM RA, a known factor for neuronal differentiation (Jacobs et 
al., 2006), under serum-starved condition for 3 days. The cells were then 
stained for CD137 and differentiation markers such as MAP-2 and β-tubulin 
III. RA induced differentiation in the Neuro-2a cells as depicted clearly with 
the increase in MAP-2 and β-tubulin III (Figures 8a and 8b). Interestingly, 
upon differentiation, not only was CD137 not induced as seen in treated N2a 
parental and N2aT/pcDNA3.0, expression of CD137 actually decreased in 
treated N2aT/muCD137 from 93.2% to 28.1% (Figure 8c). CD137L was not 
inducible upon RA treatment (Figure 8d). This suggests that inducibilty of 





































































































































































































































































Figure 8. CD137 and its ligand are not detected on parental N2a and 
transfected N2aT cells upon cell differentiation. Cells were treated with either 
DMSO (control) or 20 μM of retinoic acid (RA) in DMEM containing 2% FBS for 3 
days. Cells were then stained with PE-conjugated anti-murine CD137, PE-
conjugate anti-murine CD137L, anti-MAP-2 or anti-β-tubulin III antibodies. Stained 
cells were analysed via flow cytometry. Percentages of (a) MAP-2-positive cells, 
(b) β-tubulin III-positive cells, (c) CD137-positive cells, and (d) CD137L-positive 
cells were plotted. Grey bars are for DMSO control and black bars are for positive-
stained cells. 
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3.5 Effect of Neuro-2a neuronal cell line and microglial cell lines co-
culture 
While there have been some reports on the expression of CD137 in the CNS, 
little is known about the function of CD137 in the CNS (Reali et al., 2003; Yeo 
et al., 2012). In accordance to the abovementioned results, we sought to 
investigate the effects of CD137 expressed on neurons upon ligation with its 
ligand. As CD137 protein expression on primary neurons was less than ideal 
for further functional experiments, we employed the neuronal cell line Neuro-
2a that has been transfected to express murine CD137 (N2aT/muCD137). 
Earlier studies in our laboratory have established the expression of CD137L 
on microglia (Yeo et al., 2012). As microglia is central to the immune defence 
in the CNS, and is involved in immune surveillance, it was the most probable 
candidate to engage in CD137-CD137L interactions with CD137-expressing 
neurons in the CNS. Hence, we set up a co-culture system with transfected 
neuronal Neuro-2a and microglial BV-2 or N9 cells for our investigation of 
CD137-CD137L interaction in the CNS. 	  
3.5.1 CD137 ligation induced increased apoptosis in Neuro-2a cells 
CD137 ligation has been associated with T cell activation-induced cell death 
during early stages of inflammation (Zhang et al., 2007). With reports of 
CD137 expression found in the CNS during inflammation (Yeo et al., 2012; 
Blank et al., 2014), it is possible that cross-linking of CD137 on neurons may 
affect neuronal apoptosis. Thus, it will be worthwhile to examine the effect of 
CD137 ligation on neuronal apoptosis. In order to investigate this, transfected 
Neuro-2a cells were co-cultured with microglial BV-2 or N9 cells for 24 hours 
at a 1:1 ratio. The cells are then stained with Annexin V and 7-AAD to 






























visualise the extent of neuronal apoptosis by flow cytometry. In order to 
distinguish the cells in the co-culture, the cells were also stained for CD45, a 
common antigen for leukocytes and hence, only stain microglial but not the 
neuronal cells.  
 
In the co-culture of transfected Neuro-2a cells and BV-2, higher apoptosis 
rates were observed upon CD137 ligation. 28% of N2aT/muCD137 underwent 
early apoptosis and 10.2% undergoing late apoptosis, almost twice the 
percentage of N2aTpc/DNA3.0 experiencing early and late apoptosis at 












Figure 9. Microglia activated by neuronal CD137 induce more apoptosis in 
neurons. N2aT/pcDNA3.0 and N2aT/muCD137 cells were cultured with either N9 
or BV-2 microglial cells at 1:1 ratio for 24 hours. Cells were then stained with 
Alexa Fluor 647-conjugated Annexin V and 7-AAD antibodies. CD45 staining was 
done to distinguish neuronal and microglial cell lines. Analysis was done via flow 
cytometry. Percentages of Annexin V-positive and 7-AAD-positive cells are 
depicted in each quadrant. 
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A similar trend was seen in the co-culture of transfected Neuro-2a and N9 
cells. The percentages of N2aT/muCD137 cells undergoing early and late 
apoptosis are 36.8% and 27.5% respectively, which were higher than the 
28.1% and 12.8% for non-CD137-expressing Neuro-2a cells (Figure 9). This 
clearly indicates that this difference in apoptosis is due to CD137 ligation on 
neuronal cells. 
 
3.5.2 CD137 signalling into neurons has minimal effect on their 
apoptosis rate 
While we have shown that CD137-CD137L interaction between transfected 
Neuro-2a and microglial BV-2 or N9 resulted in neuronal apoptosis, the 
mechanism of apoptosis induction remains to be investigated. One possible 
mechanism is the direct transduction of CD137 signal into neurons upon 
CD137 ligation.  
 
In order to determine if this is the mechanism of the increased apoptosis rate, 
N2aT/pcDNA3.0 and N2aT/muCD137 were cultured on plates coated with 10 
μg/ml of agonistic anti-murine CD137 antibody clones 3H3 and 158332 for 24 
hours. Subsequently, cells were stained with Annexin V and 7-AAD to 
examine the extent of apoptosis via flow cytometry. We found that there were 
nominal differences in the apoptosis rates of N2aT/muCD137 when treated 
with isotype or agonistic 3H3 and 158332 (Figure 10). This suggests that 
neuronal apoptosis upon CD137-CD137L interaction is not due to CD137 
signal transduction into the neurons, but via other mechanisms. 
 
 















































3.5.3 Neuronal apoptosis is facilitated by ROS produced upon CD137-
CD137L interaction  
Apoptosis of Neuro-2a cells may be a result of one or a few different stimuli 
that trigger the apoptotic pathway. Earlier, we have ruled out direct CD137 
signal into the neurons as the mechanism of neuronal apoptosis upon 
CD137-CD137L interaction. Previously, our group had established that 
apoptosis of oligodendrocytes was due to ROS produced by CD137L-
activated microglia (Yeo et al., 2012). Hence, we proposed that a similar 
mechanism led to the killing of neurons, in which ROS produced upon 
CD137-CD137L interaction results in neuronal apoptosis. In order to confirm 
Figure 10 CD137 signalling into neurons has little effect on neuronal 
apoptosis. N2aT/pcDNA3.0 and N2aT/muCD137 cells were cultured on plates 
coated with 10 μg/ml of isotype or agonistic anti-murine CD137 antibodies (3H3 
and 158332) for 24 hours. Cells were then stained with Alexa Fluor 647-
conjugated Annexin V and 7-AAD antibodies. Analysis was done via flow 
cytometry. Percentages of Annexin V-positive and 7-AAD-positive cells are 
depicted in each quadrant. This experiment was repeated thrice with similar 
results. 
 	  
































this, transfected Neuro-2a cells were co-cultured with either BV-2 or N9 cells 
at a 1:1 ratio for 24 hours with and without 10,000 U/ml of catalase. Cells 
were also stained with FITC-conjugated anti-murine CD45 antibody to 
distinguish between the neuronal and microglial cells.  
 
In line with our hypothesis, it was found that ROS is required for neuronal 
apoptosis induced by CD137-CD137L interaction. Upon catalase treatment, 
the killing of CD137-expressing Neuro-2a cells when co-cultured with BV-2 
cells was significantly inhibited. N2aT/muCD137 undergoing early and late 
apoptosis decreased from 45.3% to 25.2% when treated with catalase  
(Figure 11a). A similar but less pronounced trend was seen when 
N2aT/muCD137 were co-cultured with N9 microglial cells, charting almost a 
10% decrease from 41.4% to 31.6% of N2aT/muCD137 cells undergoing both 
early and late apoptosis upon catalase treatment (Figure 11b). This clearly 
























































3.6 Interaction of microglia with T cells via CD137-CD137L mediates T 
cells proliferation and enhanced GM-CSF secretion 
Aside from CD137-expressing CNS resident cells, microglia may also interact 
with activated T cells expressing CD137. During an inflammation, a damage 
of the blood-brain barrier may result in the infiltration of activated T cells into 
the CNS. We hypothesised that these activated T cells are then able to 
interact with CD137L-expressing microglia via CD137 and CD137L 
interaction. Hence, we sought to investigate this interaction between T cells 
and microglia. In order to do that, primary T cells isolated from murine 
splenocytes were co-cultured with the microglia cell lines BV-2 and N9 for 5 
Figure 11 Microglia activated by interacting with neuronal CD137 stimulate 
ROS production, which is responsible for apoptosis in neurons. (a) BV-2 or 
(b) N9 cells were co-cultured with transfected N2a cells at a 1:1 ratio for 24 hours 
with or without 10,000 U/ml of catalase. Frequency of N2a apoptosis is 
determined by gating on non-CD45 stained cells with Annexin V/7-AAD staining 
via flow cytometry. Percentages of Annexin V-positive and 7-AAD-positive cells 
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days with or without CD137L blocking antibody. TKS-1 is an anti-CD137L that 
blocks CD137-CD137L interaction. Prior to co-culture, T cells were stained 
with CFSE to allow proliferation analysis to be done via flow cytometry. The 
supernatants were collected and tested for GM-CSF, IFN-γ, MCP-1, M-CSF 
and TNF secretion. 
 
Upon treatment with TKS-1, there was an increase of almost 20% in the 
mean fluorescence intensity (MFI) of CFSE when T cells are co-cultured with 
BV-2. The increase in MFI upon CD137L blockade showed that there were 
less T cells undergoing proliferation when CD137-CD137L interaction is 
inhibited. A drop in the percentage of proliferating cells upon CD137L 
blockade from 65.7% to 57.4% further strengthened the hypothesis that 
CD137-CD137L interaction plays a role in microglia-mediated T cell 
proliferation. A similar trend was seen when T cells were co-cultured with N9 
cells. The MFI of the T cells revealed a substantial increase of 25% from 4850 
to 6128 despite a small 5% decrease in the percentage of proliferating cells 
(Figure 12a).  
 
Enhanced cytokine secretion was observed upon co-culture of T cells and 
microglia cells for GM-CSF, MCP-1, M-CSF and TNF. Interestingly, there was 
a significant decrease in IFN-γ levels when T cells were subjected to a 
microglial environment. When interaction of CD137 and its ligand is blocked, 
there was minimal difference in cytokine levels with the exception of GM-CSF. 
 
There was a substantial decrease in GM-CSF levels from 105 ± 11.2 pg/ml to 
23 ± 4.0 pg/ml when CD137-CD137L interaction between T cells and BV-2 












cells were blocked (Figure 12b, left panel). A similar but less pronounced 
trend was also seen in the co-culture of T cells and N9 cells in which levels of 
GM-CSF dropped from 16 ± 2.7 pg/ml to non-detectable levels upon CD137L 
blockade (Figure 12b, right panel). For both co-cultures, GM-CSF levels were 
comparable to basal GM-CSF levels of T cells when interaction of CD137 and 
its ligand was blocked. 
 
This indicates that CD137-CD137L interaction mediates microglia-mediated T 




























































Figure 12. CD137-CD137L interaction partially contributes to T cell 
proliferation and induces enhanced GM-CSF secretion. (a) Murine T cells 
isolated from the spleen were cultured with either BV-2 or N9 at a 10:1 ratio for 5 
days. T cells were stained with 3μM of CFSE prior to co-culture. After 5 days, cells 
were harvested and stained for CD3. Stained cells were analysed via flow 
cytometry. Percentages and mean fluorescence intensity (MFI) of proliferating 
cells are reflected in each graph. Open histograms are for fixed CFSE cells as 
control and filled grey histograms are for CFSE-stained cells. (b) Supernatants of 
co-culture were analysed by ELISA for GM-CSF, IFN-γ, MCP-1, M-CSF and TNF. 
Means ± standard deviations of triplicate measurements are depicted (*p<0.05, 
**p<0.01; ND: non-detectable). These experiments were repeated at least three 
times with similar results. 
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3.7 Treatment of hESC-derived dopaminergic neurons for CD137 
expression 
Preliminary studies in the murine system thus far have suggested that murine 
neuronal CD137 in the CNS does exist and plays a role in neuronal apoptosis 
during CNS inflammation. With that in mind, we followed up the murine 
studies with human studies. Firstly, we attempted to investigate the 
expression of human CD137 on neurons. In order to verify the existence of 
human neuronal CD137, we employed hESC–derived dopaminergic neurons. 
These hESC-derived dopaminergic neurons were differentiated for 16 days 
prior to treatment. Post differentiation, treatment of these neurons included 
basic FGF, NGF-β, PMA or left untreated overnight. The cells were then 
stained for CD137 before being analysed by flow cytometry. It was observed 
that CD137 was undetectable on both untreated and treated dopaminergic 
neurons (Figure 13).  
 
3.8 Treatment of astrocytes for CD137 expression 
Recently, Blank et al. (2014) reported an upregulation of CD137 expression in 
astrocytes found in human gliomas. This brought about an exciting possibility 
that CD137 expression in human CNS may not be on neurons but on 
astrocytes instead. Hence, we decided to explore this new prospect and 
endeavoured to detect CD137 protein expression on human astrocytic cell 
lines and primary human astrocytes. 
 
3.8.1 CD137 expression is undetected on CRL1718 and U373-MG 
The astrocytoma cell lines, CRL1718 and U373-MG, were serum-starved or 
treated with PMA, IL-1β and TNF or left untreated for 48 hours. CD137 




















staining was then done using PE-conjugated anti-human CD137 antibody. 
Flow cytometry was used for the analysis. Minimal CD137 expression was 
observed on both CRL1718 and U373-MG cell lines despite various 




















Figure 13. Expression of CD137 protein could not be detected on human 
embryonic stem cell (hESC)-derived dopaminergic neurons. Cells were 
differentiated from hESCs for 16 days before treatment with basic FGF, NGF-β, 
PMA or left untreated overnight. Cells were then stained with anti-β-tubulin III 
antibody and PE-conjugated anti-human CD137 or CD137L antibodies. Stained 
cells were analysed via flow cytometry. Percentages of β−tubulin III-positive, 
CD137-positive cells are depicted in the appropriate quadrant. 
 	  












































Figure 14. CD137 protein is not detected on astrocytic cell lines upon 
treatment. (a) CRL1718 and (b) U373-MG were left untreated, serum starved or 
treated with PMA, IL-1β or TNF for 48 hours. Cells were then stained with PE-
conjugated anti-human CD137 antibody. Stained cells were analysed via flow 
cytometry. Percentages of CD137-positive cells are reflected in each graph. Open 
histograms are for isotype control and filled grey histograms are for CD137 
stained cells. 
 	  












3.8.2  CD137 expression on primary human astrocytes was not 
induced despite treatment 
Primary human astrocytes were subjected to the same conditions as stated in 
Section 3.7.1. The astrocytes were then stained and tested for CD137 
expression via flow cytometry. Flow analysis revealed surprising results with 
mean fluorescence intensity of isotype staining far exceeding that of CD137 
staining (Figure 15a). In order to circumvent this, immunocytochemistry was 













































Figure 15. CD137 protein is not detected on primary human astrocytes upon 
treatment. Cells were left untreated, serum starved or treated with PMA, IL-1β or 
TNF for 48 hours. Cells were then stained with PE-conjugated anti-murine CD137. 
Stained cells were analysed via flow cytometry. Percentages of CD137-positive 
cells are reflected in each graph. Open histograms are for isotype control and 
filled grey histograms are for CD137 stained cells. (b) Cells were left untreated or 
treated with either PMA or IL-1β for 48 hours. Immunocytochemistry staining was 
performed on treated cells with anti-human CD137 antibody and DyLight 649-
conjugated anti-rat IgG secondary antibody. The white scale bar represents 50 
μm.  
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The primary cells were treated with PMA, IL-1β or left untreated for 48 hours 
before they were fixed, permeabilised and stained for CD137. Similar to our 
findings in flow cytometry, the isotype staining acquired higher fluorescence 
intensity as compared to CD137 staining for the primary cells (Figure 15b). 
Peculiarly, the positive control cells used for this experiment, CD137-
expressing CHO cells, attained expected staining pattern in which 
fluorescence for isotype was much lower than that of CD137 staining. 
 
As we suspected that the problem of isotype unspecific staining lies in the 
isotype antibody used, we utilised a different isotype antibody for the next 
experiment. Another batch of primary human astrocytes were treated with 
various reagents, cytokines or supernatants of astrocytic cell lines CRL1718 
and U373-MG for 48 hours. Immunocytochemistry staining was done and 
fluorescence was visualised using a fluorescence microscope. Little or no 
unspecific staining was observed for isotype-treated cells. In tandem with this 
observation, CD137 protein could not be detected on the primary human 
astrocytes despite the numerous treatments and conditions the cells were 













































































IL-10 + TGFβ  
(10 ng/ml)"





























Figure 16. CD137 protein could not be detected on primary human 
astrocytes upon treatment. Cells were left untreated or treated with (a) 
reagents, (b) cytokines or (c) supernatants of astrocytic cell lines, CRL1718 and 
U373-MG for 48 hours. Immunocytochemistry staining was performed on treated 
cells with anti-human CD137 antibody and DyLight 649-conjugated anti-rat IgG 
secondary antibody. The white scale bar represents 50 μm.  	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3.9 Effect of CD137-CD137L interaction between primary T cells and 
the monocytic cell lines 
We have previously shown that CD137-CD137L interaction aids microglia-
induced T cell proliferation and that it induces the production of GM-CSF in 
the murine system. Hence, we were interested to see if similar outcomes are 
observed in the human system. In order to investigate the effect on CD137-
CD137L interaction between microglia and T cells in the human system, a co-
culture of primary human T cells and a monocytic cell line was performed. As 
primary human microglia was not an available option for functional 
experiments and human microglial cell lines are challenging to procure, we 
used the monocytic cell line U937 instead of microglia. Since microglia and 
U937 cells are both of monocytic origin (Malm et al., 2010), this replacement 
seemed to be justified. 
 
3.9.1 Treatment with anti-CD137 antibody P2F2 enhanced GM-CSF 
secretion while dampening IL-17A production 
Primary human T cells were isolated from PBMCs stimulated with OKT3, an 
anti-CD3 antibody for 24 hours. The T cells were then co-cultured with U937 
at a 10:1 ratio for a further 24 hours. Co-cultures were treated with either 10 
μg/ml of isotype antibody or anti-CD137 antibody P2F2. After 24 hours, the 
supernatants were collected and subsequently tested for levels of GM-CSF 
and IL-17A.  
 
It was found that there was an increase in GM-CSF secretion when 
interaction of CD137 and its ligand between the two cells was interrupted 




(Figure 17A). Intriguingly, this observation is the opposite of what was 
observed in the human system as mentioned in Section 3.6.  
 
Other than GM-CSF, IL-17A involvement in some neurodegenerative 
diseases such as multiple sclerosis has been well established (El-Behi et al., 
2011; Zepp et al., 2011). Hence, we determined if treatment with anti-CD137 
antibody has any effect on IL-17A induction. As seen in Figure 17b, treatment 
with P2F2 diminished IL-17A secretion. 
 
This implies that treatment with anti-CD137 antibody gives rise to divergent 
effects with regards to GM-CSF and IL-17A production. However, it still 
remains to be determined if this effect is due to a signal transduction into T 
cells via CD137 or the inhibition of CD137-CD137L interaction. 
 







Figure 17. Treatment with anti-CD137 antibody P2F2 induces enhanced GM-
CSF secretion with decreased IL-17A secretion. Human PBMCs were 
stimulated with 5 ng/ml of OKT3 for 24 hours. T cells were then isolated from the 
stimulated PBMCs and co-cultured with monocytic cell line, U937 at a 10:1 ratio 
for 24 hours. Co-cultures were treated with either 10 μg/ml of isotype or P2F2. 
Supernatants of co-culture were analysed by ELISA for (a) GM-CSF and (b) IL-
17A. Means ± standard deviations of triplicate measurements are depicted 
(*p<0.05, **p<0.01; ND: non-detectable). 	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3.9.2 Treatment with anti-CD137L antibody P1A7 mimicked anti-CD137 
antibody P2F2 treatment 
As mentioned above, the increase in GM-CSF and decrease in IL-17A levels 
upon anti-CD137 antibody treatment could be due to two reasons: the direct 
CD137 signalling into T cells or the inhibition of CD137-CD137L interaction. 
Hence, we decided to treat the co-cultures with different clones of anti-
CD137L antibodies to investigate if similar effects will be resulted. The co-
cultures were set up as described in Section 3.9.1. However, instead of 
treating with anti-CD137 antibody, these co-cultures were treated with anti-
CD137L antibodies (P1A7, P1G1, P2D5, C65-485, 41B436 or 5F4) or its 
isotype at a concentration of 10 μg/ml for 24 hours.  
 
It was observed that 3 out of the 6 anti-CD137L antibodies resulted in 
enhanced GM-CSF secretion (Figure 18a). 1 out of the 6 antibodies gave rise 
to decreased IL-17A levels (Figure 18b). Fascinatingly, anti-CD137L antibody 
P1A7 showed similar results when co-culture was treated with anti-CD137 
antibody P2F2. This suggests that the change in GM-CSF and IL-17A 
cytokine profiles is due to the interruption in CD137-CD137L interaction and 
not direct CD137 signalling into T cells. 
 
3.9.3 CD137-CD137L interaction failed to enhance RORγt expression 
Codarri et al. (2011) reported GM-CSF as an essential cytokine for the 
induction of experimental autoimmune encephalomyelitis (EAE) in mice. This 
production of GM-CSF by T cells is driven by the transcription factor RORγt. 
Hence, we were interested to find out if the enhanced GM-CSF production 






shown in Section 3.9.1 was due to enhanced RORγt expression induced by 


















Human T cells were isolated from PBMCs stimulated with 5 ng/ml of OKT3 for 
24 hours. The T cells were then co-cultured with U937 at a 10:1 ratio for a 
further 16 hours. Co-cultures were treated with either 10 μg/ml of isotype 
Figure 18. Treatment with anti-CD137L antibodies induces enhanced GM-
CSF secretion but not IL-17A secretion. Human PBMCs were stimulated with 5 
ng/ml of OKT3 for 24 hours. T cells were then isolated from the stimulated PBMCs 
and co-cultured with monocytic cell line, U937 at a 10:1 ratio for 24 hours. Co-
cultures were treated with 10 μg/ml of isotype or one of the anti-CD137L 
antibodies (P1A7, P1G1, P2D5, C65-485, 41B436, 5F4). Supernatants of co-
culture were analysed by ELISA for (a) GM-CSF and (b) IL-17A. Means ± 
standard deviations of triplicate measurements are depicted (*p<0.05, **p<0.01; 
ND: non-detectable). 	  










antibody (MOPC) or anti-CD137L antibodies 5F4 and C65-485. After 16 
hours, the cells were stained extracellularly for CD4 and stained intracellularly 
for RORγt. Stained cells were then analysed via flow cytometry. 
 
No increase in RORγt was observed despite treatment with anti-CD137L 
antibodies (Figure 19). This suggests that CD137-CD137L interaction may 































Figure 19. Treatment with anti-CD137L antibodies did not enhance RORγt 
expression. Human PBMCs were stimulated with 5 ng/ml of OKT3 for 24 hours. 
T cells were then isolated from the stimulated PBMCs and co-cultured with the 
monocytic cell line U937 at a 10:1 ratio for 16 hours. Cells were stained for CD4, 
followed by intracellular staining for RORγt. Percentages of RORγt-positive cells 
are depicted in each graph. Open histograms are for isotype control and filled 
histograms are for RORγt stained cells. 	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4 DISCUSSION 
The role of CD137-CD137L interaction in inflammation has been convincingly 
established within the past decade. While there seemed to be conflicting 
reports as to whether this interaction worsens or alleviates inflammation and 
hence, the pathogenesis of a disease, CD137-CD137L interaction usually 
involves immune cells partaking an active role in regulating inflammation. 
Most research done with regards to this interaction has been focused on the 
leukocytes including T cells, NK cells, dendritic cells, as well as monocytes 
(Schwarz et al., 1995; Melero et al., 1998; Kienzle & von Kempis, 2000; 
Futagawa et al., 2002).  
 
Although it has been almost a decade since the expression of CD137L was 
first reported on APCs, the effects of CD137-CD137L interaction involving 
antigen-presenting microglia has not been studied. Hence, this study aims to 
broaden the limited knowledge on the role of CD137-CD137L interaction in 
microglia-mediated immune responses.  
 
4.1 Murine CD137 is expressed on neurons in CNS in vivo 
There is not much literature on CD137 expression in the CNS. While CD137 
expression has been reported on cells of CNS origin such as neurons and 
neuronal stem cells, these are cells cultured in vitro and there has been little 
convincing in vivo evidence of CD137 expression in the CNS (Reali et al., 
2003; Yun et al., 2013). Hence, it was imperative for us to first establish the 
expression of CD137 in vivo. 
 
In order to do this, we first attempted to detect CD137 protein in lysates of 
various sections of the murine brain, mainly cortex, hippocampus, forebrain, 
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cerebellum, pons and medulla. We also included lysate of cerebellar neurons 
isolated from murine pups. CD137 protein could not be detected in these 
lysates. One of the reasons may be the low expression of CD137 in the CNS. 
Furthermore, with the brain having the highest abundance of lipids after 
adipose tissue due to the presence of myelin	   (Kurban et al., 2007), the 
concentration of CD137 protein in the lysates was further diluted. This makes 
it even more challenging to detect CD137 protein in the CNS via western blot. 
 
A more sensitive method was required to detect CD137 expression in the 
CNS. Hence, we employed immunofluorescence in which we were able to 
view CD137 expression at the cellular level and identify its localisation within 
the CNS. Preliminary evidence from our group suggested that expression of 
CD137 could be found in the cerebellum, specifically on cells that reside in 
the Purkinje layer. Purkinje cells are GABAnergic neurons, crucial for motor 
coordination, as it is the only output of the cerebellar cortex (Dusart et al., 
2006).  Hence, we hypothesised that CD137 is expressed on Purkinje cells. A 
double immunofluorescence staining was done on WT murine tissue sections 
to detect CD137 and calbindin-D28k. Calbindin-D28k served as a marker for 
Purkinje cells due to its specific expression on Purkinje cells in the cerebellum 
(Bastianelli, 2003; Kim et al., 2009). Co-localisation of CD137 and calbindin-
D28k, as seen from the overlapping yellow staining of red and green 
fluorescence, verified the hypothesis of CD137 expression on Purkinje cells.  
 
	   65 
4.2 CD137 protein expression in CNS differed in wild-type and 
diseased mice 
With the establishment of CD137 expression in the cerebellum, it was 
tempting to explore the possibility of CD137 expression in other areas of the 
CNS as well as to examine if a disease status of the mice affects CD137 
expression. Thus, we stained murine midbrain tissue slices from C57BL/6 
mice in which a 1-hour middle cerebral artery occlusion had been performed 
and was subsequently reperfused for 24 hours (Low et al., 2014). These 
tissues were then stained for CD137 protein. However, CD137 protein was 
not detectable in the midbrain. It is possible that the tissue section stained did 
not contain the cerebral infarct. Hence, we decided to do a western blot on 
lysates of contralateral and ipsilateral hemispheres (with respect to the 
infarct) in order to detect for CD137 protein expression. Similarly, no CD137 
protein expression was detected, possibly due to similar reasons discussed in 
the second paragraph of Section 4.1. 
 
Another possibility as to why CD137 could not be detected could be due to 
CD137 not being expressed in the midbrain. Therefore, we examined another 
murine CNS disease model for CD137 expression. Mice with DMT-1 
overexpression served as an alternative murine model to study Parkinson’s 
disease. Parkinson’s disease has been associated with increased iron 
deposition in the substantia nigra (Riederer et al., 1989). This increase in iron 
content saw a corresponding increase in the expression of DMT-1, a divalent 
metal transporter, and subsequently, neuronal loss (Salazar et al., 2008). 
Hence, mice with DMT-1 overexpression recapitulate neurodegenerative 
conditions seen in numerous CNS-related diseases.   
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Tissue sections from the striatum of mice overexpressing DMT-1 were 
stained for CD137 and β-tubulin III, a neuronal marker. Co-localisation of the 
two proteins was observed, indicating that CD137 is expressed on neurons in 
the striatum. Further quantification of staining revealed that despite 
comparable percentages of neurons expressing CD137 between WT mice 
and mice overexpressing DMT-1, neuronal CD137 in striata of mice 
overexpressing DMT-1 were more intensely expressed, covering a larger 
area in neurons. This suggests that under pathological conditions, neuronal 
CD137 is upregulated. While previous studies have reported an elevation of 
soluble CD137 in the CSF or serum (Sharief, 2002; Jung et al., 2004; Furtner 
et al., 2005; Yan et al., 2013) under pathological conditions, this is the first 
time in which membrane-bound CD137 was shown to be upregulated in the 
CNS during disease. 
 
4.3 CD137 was not inducible in primary murine CNS cells  
We have demonstrated thus far that CD137 is expressed on neurons in vivo 
and is upregulated during disease. The next step was to investigate if CD137 
in the CNS has any biological functions that may contribute the propagation 
or alleviation of diseases. This entailed in vitro studies and hence, cells of 
CNS origin expressing CD137 were required to proceed with functional 
studies. While we have previously detected CD137 on neurons, expression of 
CD137 was also found on cells that were not positive for neuronal markers. 
To ensure that we do not exclude other CNS cell populations in the search for 
CD137-expressing, CNS-resident cells, we examined expression of CD137 
on dissociated tissue cultures of murine brains from WT, CD137-/- and 
CD137L-/- mice.  
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Under unstimulated conditions, all the dissociated brain tissue cultures were 
tested negative for CD137 protein. This was not surprising as CD137 
expression is activation-dependent and modulated by specific stimuli (Kempis 
et al., 1997). We then proceeded to treat the cultures with LPS, PMA or Poly 
I:C for 24 hours. Likewise, no CD137 expression was detected on these 
dissociated brain tissue cultures. While it is understandable that CD137 was 
undetected in dissociated brain tissue culture from CD137-/- mice, it was 
peculiar that both WT and CD137L-/--derived CNS cells did not seem to 
express CD137 at all. This may be due to the dissociation method used. We 
did not employ the usual method of using enzyme-based digestion to 
dissociate the brain, which may have been gentler on the cells (Lee & 
Tansey, 2013). Moreover, the dissociation process may have been too 
rigorous as mechanical disruption was employed as the method of 
dissociation. This might have damaged the membrane of the cells and hence, 
compromised the integrity of CD137 protein.  
 
With these caveats in mind, we decided to re-focus on neuronal CD137 by 
examining the expression of CD137 on primary murine neurons. This time, 
the primary murine neurons, kindly provided by Associate Professor Thiruma 
Arumugam, were isolated and cultured using an established protocol (Okun et 
al., 2007; Lok et al., 2015). Since there were difficulties in detecting CD137 
protein, we wanted to rule out the possibility that neurons might not even 
express CD137 mRNA to begin with. Hence, we tested the primary murine 
neurons; both untreated and treated conditions, for CD137 mRNA expression. 
CD137 mRNA was detected for all conditions, including untreated primary 
murine neurons. While CD137 mRNA has been detected in human fetal 
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neurons previously (Reali et al., 2003), this is the first in which murine 
neurons has been reported to express CD137 mRNA. Although mRNA may 
not necessarily be translated into protein, nonetheless, this provided a basis 
to examine CD137 protein expression on primary murine neurons. 
 
In order to investigate the expression of CD137 protein on primary murine 
neurons, the cells were stimulated with various reagents and cytokines for 24 
hours. Cycloheximide was chosen as one of the reagents used for the 
induction of CD137 protein in the cells. Although cycloheximide has 
traditionally been regarded as a protein synthesis inhibitor (Siegel & Sisler, 
1963), it was previously reported to induce protein expression in neurons 
(Furukawa et al., 1997).  
 
Despite the different treatments, CD137 protein was not detected in the 
primary murine neurons. However, there seemed to be a slight induction of 
CD137 protein in the neurons treated with PMA or RA. PMA activates protein 
kinase C, leading to a whole range of downstream signalling. It has been 
demonstrated to induce CD137 expression in T cells and other primary 
lymphocytes (Schwarz et al., 1995). RA is a well-known factor essential for 
the differentiation of neurons (Janesick et al., 2015). It binds to RA receptor, 
which may in turn lead to the induction of gene transcription and protein 
expression (Balmer & Blomhoff, 2002).  
 
4.4 CD137 expression is affected by neuronal differentiation 
With all that said, the magnitude of CD137 induction on the treated primary 
murine neurons is puzzling. This slight induction may be due to the 
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differentiation status of these primary neurons. CD137 expression in 
chondrocytes has been shown to decrease as chondrocytes eventually 
differentiated to take on a fibroblastoid phenotype (Kempis et al., 1997). This 
phenomenon may have been mimicked in the primary neurons. Prior to the 
experiment, the primary murine neurons were left in culture for 10 days, in 
which differentiation could have taken place.  
 
In order to ascertain if CD137 expression is a function of neuronal 
differentiation, we examined the expression of CD137 on Neuro-2a cells: 
parental Neuro-2a cells (N2a parental), Neuro-2a transfected to express 
CD137 (N2aT/muCD137) and Neuro-2a transfected with empty vector 
(N2aT/pcDNA3.0). While we found CD137 in neurons in vivo, N2a parental 
cells did not express it despite various treatments. This supported previous 
report in which inducibility of CD137 in brain-derived cell lines was absent 
(Schwarz et al., 1995). Hence, Neuro-2a cells had to be transfected in order 
to obtain a neuronal cell line that expresses CD137. We employed RA to 
induce neuronal differentiation in the cells. MAP-2 and β−tubulin III were used 
as markers of neuronal differentiation (Bhat et al., 2006; Hsu et al., 2014).   
 
As expected, Neuro-2a cells treated with RA had increased expression of 
MAP-2 and β−tubulin III, indicating neuronal differentiation in these cells. 
However, this differentiation brought about a significant decrease in CD137 
protein expression as seen from the drop in the percentage of 
N2aT/muCD137 cells tested positive for CD137. This is in agreement with the 
finding reported on the differentiated chondrocytes mentioned above (Kempis 
et al., 1997). 
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In view of our finding whereby CD137 expression was upregulated under 
pathological conditions, we hypothesised that neurons may have gone 
through a process of dedifferentiation under these conditions and hence, 
resulting in the upregulation of CD137 expression. Friedmann-Morvinski et al. 
(2012) reported that neurons undergo dedifferentiation upon genetic alteration 
to induce tumour formation. Since tumours have been shown to associate 
with upregulation of CD137 (Ho et al., 2013), it is plausible that 
dedifferentiated neurons expressed higher levels of CD137. Further studies 
can be conducted to examine how neuronal CD137 expression correlates 
with different differentiation markers in vivo. 
 
4.5 CD137-CD137L interaction established a pro-apoptotic and pro-
inflammatory environment in murine CNS 
With the existence of CD137 expression in the CNS ascertained, the next 
step was to investigate the function of neuronal CD137 in the CNS. CD137, 
being a receptor, requires a ligand to activate downstream signalling.  While 
there may be many ligands to a receptor, the most studied ligand for CD137 
is CD137L. Our group has previously shown that microglia expresses 
CD137L (Yeo et al., 2012). While the effects of CD137L-activated microglia 
has been studied using recombinant CD137 protein, the consequences of 
CD137–CD137L interaction between two CNS-derived cells have not be 
reported thus far.  
 
While such experiments are ideally performed using CD137-expressing 
primary neurons as well as CD137L-expressing primary microglia, levels of 
CD137 expression on our primary murine neurons were not suitable for the 
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experiment. Furthermore, due to the minimal proliferation of primary cells, a 
large number of mice would have to be sacrificed in order to obtain enough 
neurons and microglia for the set-up. As we have yet to obtain any 
preliminary data, utilisation of neuronal and microglia cell lines is preferable to 
get an indication as to how CD137-CD137L interaction in the CNS exert its 
effects. Hence, neuronal Neuro-2a transfected cells (N2aT/pcDNA3.0 and 
N2aT/muCD137) were co-cultured with microglial BV-2 or N9 cells to 
investigate this interaction. 	  	  
4.5.1 Neuronal apoptosis upon CD137-CD137L interaction is not due to 
CD137 signalling into neurons 
A major finding by our group is that CD137L-activated microglia induces 
oligodendrocyte apoptosis (Yeo et al., 2012). Hence, we examined if CD137L-
activated microglia would have a similar effect on neuronal cells. As 
expected, higher neuronal apoptosis was observed upon CD137-CD137L 
interaction between CD137-expressing Neuro-2a and microglial BV-2 or N9 
cells.  
 
Some members of the TNF receptor family have been associated with the 
induction of apoptosis via their death domains. However, there is another 
group of TNF receptors that binds to TNF receptor associated factors 
(TRAFs), which is involved in anti-apoptotic signalling (Gravestein & Borst, 
1998). CD137 has been revealed to interact with several TRAF proteins such 
as TRAF1 and TRAF2 (Arch & Thompson, 1998). The more intensively 
studied TRAF2 binds to CD137 via TRADD adapter and associates itself with 
RIP1. The bound TRAF2, together with RIP1, then proceeds to trigger a 
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cascade of signalling which eventually leads to NF-κB activation (Au & Yeh, 
2007). NF-κB then translocates into the nucleus to induce the gene 
transcription of anti-apoptotic proteins such as c-IAPs, c-FLIP and Bcl-2 
(Karin & Lin, 2002).  
 
However, there are two sides to every coin. In murine ischemic models, 
several groups have demonstrated the induction of neuronal cell death 
following neuronal NF-κB activation (Zhang, Potrovita, et al., 2005; Sarnico et 
al., 2009). Hence, there is a possibility that the neuronal death observed upon 
CD137-CD137L activation was due to CD137 signalling into the neurons and 
the subsequent induction of NF-κB activation. In order to test this hypothesis, 
CD137 signalling was induced in N2aT/pcDNA3.0 and N2aT/muCD137 using 
agonistic anti-murine CD137 antibodies. It was found that CD137 signalling 
into neurons had minimal or no effect in the induction of neuronal apoptosis. 
This suggests that microglia is a key player in mediating neuronal cell death 
upon CD137-CD137L interaction. 
 
4.5.2 ROS produced by CD137L-activated microglia is responsible for 
neuronal apoptosis 
A notable characteristic of the CD137-CD137L system is its ability of 
generating reverse signalling through CD137L, and thereby making it a 
bidirectional signalling system (Schwarz, 2005). As signalling through both 
CD137 and its ligand is generally regulated through CD137 expression 
(Schwarz, 2007), many studies on CD137-CD137L system were primarily 
focused on CD137 receptor. Recently, more studies on CD137L have been 
emerging, showing that CD137L reverse signalling is as crucial in influencing 
	   73 
the process of inflammation (Ju et al., 2003; Kang et al., 2007; Harfuddin et 
al., 2013). 
 
Martinez Gomez et al. (2012) demonstrated that CD137L-/- mice were 
protected from EAE, a murine model for human multiple sclerosis and 
neuroinflammation. In addition, the absence of CD137L saw reduced 
microglia activation and lower numbers of apoptotic oligodendrocytes in EAE 
(Yeo et al., 2012). This indicates that CD137L on microglia plays a pivotal role 
in the induction of neuroinflammation and the apoptosis of surroundings cells. 
 
It was previously reported that CD137L-activated APCs are able to induce 
apoptosis of surrounding cells via ROS (Kwajah et al., 2011; Yeo et al., 
2012). Therefore, we predicted that the neuronal apoptosis observed upon 
CD137-CD137L interaction was mediated by ROS from CD137L-activated 
microglia. As expected, by scavenging ROS using catalase, apoptosis of 
neurons was significantly reduced upon CD137-CD137L interaction. This 
supports evidence previously found attributing neuronal cellular damage in 
CNS-related disorders to ROS (Halliwell, 2006; Hsieh & Yang, 2013).  
 
4.5.3 TNF in CD137L-mediated neuronal apoptosis: For better or for 
worse? 
While production of ROS is one of the mechanisms by which activated 
microglia exerts its neurodegenerative influence as shown above, these 
microglia also secrete a whole range of pro-inflammatory molecules, which 
aggravate neuroinflammatory pathogenesis. One of the pro-inflammatory 
cytokines secreted by activated microglia is TNF (Tambuyzer et al., 2009). 
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CD173L seemed to play an important role in regulating TNF production. Kang 
et al. (2007) previously reported that CD137L is essential for sustained TNF 
production. Furthermore, Yeo et al. (2012) demonstrated that CD137L-
activated microglia secreted higher levels of TNF.  In addition, reduced TNF 
secretion was induced when CD137L-/- draining lymph node cells were 
restimulated in culture (Martinez Gomez et al., 2012). Our previous studies 
also showed enhancement of TNF secretion with the presence of CD137-
CD137L interaction between Neuro-2a and microglial cell lines (data not 
shown). 
 
This has implications on neuronal apoptosis as neurons express receptors for 
TNF (Sipe et al., 1996). TNF has been revealed to mediate neuronal 
apoptosis via the same TRADD adapter that associates with CD137 (Swarup 
et al., 2007). Moreover, neural precursor cells (NPCs) incubated with 
activated microglia-conditioned media saw lower apoptosis rates when the 
conditioned media was treated with TNF-neutralising antibody, indicating that 
TNF is potent in inducing apoptosis of NPCs (Guadagno et al., 2013). In vivo, 
higher levels of TNF found in CSF and sera of patients with 
neurodegenerative diseases such as multiple sclerosis and Parkinson’s 
disease further suggest a neurotoxic role of TNF during disease (McCoy & 
Tansey, 2008).  
 
Aside from neurons, TNF also has the ability to directly act on microglia. 
Similar to neurons, microglia bears TNF receptors too, through which TNF 
may exert its effect on. TNF has been reported to mediate microglia 
proliferation and activation (Mander et al., 2006). As activated microglia is a 
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major source of TNF in the CNS during inflammation (Kielian & Drew, 2005), 
TNF acts on microglia in an autocrine or paracrine manner. A self-
perpetuating cycle of microglia activation can hence be established, leading 
to prolonged activation of microglia. This phenomenon has been described by 
Kuno et al. (2005). Persistent microglia activation has been associated with 
numerous CNS-related diseases, including Parkinson’s disease and multiple 
sclerosis (Block & Hong, 2007; Friese & Fugger, 2007). 
 
While not much has been reported on it, TNF is also able to exert 
neuroprotective effects. Whether TNF exhibit a neuroinflammatory or 
neuroprotective effect depends on the form of TNF that is present. Soluble 
TNF is generally associated with CNS inflammation via its binding to TNF 
receptor 1 (TNFR1) whereas the binding of transmembrane TNF to TNF 
receptor 2 (TNFR2) promotes neuronal survival (Fischer & Maier, 2015). 
Ligand binding to the each of the TNF receptors triggers different signalling 
cascades, and hence, the different fates experienced by neurons. In the MS 
murine model, Taoufik et al. (2011) demonstrated that transmembrane TNF 
conferred neuroprotection via NF-κB and protected mice from EAE. As 
mentioned before in section 4.5.1, survival of neurons via NF-κB is attributed 
to the expression of various anti-apoptotic proteins. This differs from TNFR1, 
in which it signals through its cytoplasmic death domain to induce cell 
apoptosis (Figiel, 2008). With both soluble and transmembrane TNF at play, 
the fate of neurons depends on the dominancy of a particular TNF receptor 
subtype expressed on the neurons (Yang et al., 2002).  
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For this study, only levels of soluble TNF have been tested via ELISA. It 
would be of interest to find out if CD137 direct signalling has any effect on the 
expression of TNFR1 and TNFR2 on neurons as well as the effect of CD137L 
reverse signalling on transmembrane TNF expression on microglia. As 
TNFR2 is involved in neuroprotection, selective TNFR2 agonist could be 
administered in an attempt to promote neuronal survival. In fact, Fischer et al. 
(2011) constructed a soluble TNFR2 agonist, TNC-scTNFR2, and showed that 
it was able to rescue neurons from cell death induced by oxidative stress. 
This is relevant to our study, as we have shown that ROS is required to 
induce apoptosis in Neuro-2a cells. Further experiments may be carried out to 
examine the effect of selective TNFR2 agonists on ROS-mediated neuronal 
cell death induced by CD137L-activated microglia. 
 
4.5.4 CD137L-activated microglia facilitates T cell proliferation and 
GM-CSF production 
During neuroinflammation, the blood-brain barrier is sometimes 
compromised. This allows for the infiltration of T cells into the CNS. If 
activated, these infiltrating T cells would express CD137, providing an 
additional source of CD137 in the CNS. Microglia would then be able to 
interact with these infiltrating T cells. While the effects of CD137 direct 
signalling on T cells in the presence of numerous CD137L-expressing APCs 
has been well investigated, there has not been a study done on the effects of 
T cells and microglia interaction via CD137-CD137L signalling system. 
Hence, we attempted to shed some light on this CD137/CD137L-mediated 
interaction.  
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Other than T cell activation, CD137 signalling is also known to induce 
proliferation in T cells (Schwarz et al., 1995). In line with previous reports, we 
showed that inhibiting ligation of CD137 on T cells to CD137L on microglia 
reduced proliferation of T cells. However, the change in T cells proliferation 
almost went unnoticed, and this may be due to the production of nitric oxide 
(NO) and prostaglandins. Juedes and Ruddle (2001) observed that T cell 
proliferation was inhibited by NO produced by APCs. This was further 
supported with a study done by Bai et al. (2009) in which it was demonstrated 
that NO is involved in inhibition of T cell proliferation in the presence of 
microglia. Aside from that, activated microglia was also found to produce 
prostaglandins, which resulted in reduced T cell proliferation (Carson et al., 
1999). This may have resulted in the net effect of T cell proliferation caused 
by CD137 signalling to be diminished by NO and prostaglandins produced by 
microglia. Hence, in this case, inhibiting CD137 signalling may have minimal 
effect on T cell proliferation.  
 
Future work includes testing the cultures for NO and prostaglandin levels. 
Inhibition of NO and prostaglandins can then be performed to see the extent 
of involvement on CD137-mediated T cell proliferation. 
 
A hallmark of activation is the production of cytokines. Therefore, we tested 
the levels of several cytokines such as GM-CSF, IFN-γ, MCP-1, M-CSF and 
TNF. Firstly, we observed that upon co-culture with microglia, production of all 
the cytokine tested was enhanced with the exception of IFN-γ. Microglia has 
been reported to be very effective in promoting Th1 cytokine production by T 
cells (Carson et al., 2005). Hence, while the enhanced production of the 
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cytokines was expected, the drop in IFN-γ levels upon co-culture with 
microglia was unexpected. This may be due to the presence of IL-10. Upon 
CD137-CD137L interaction, microglia becomes activated. Activated microglia 
then secrete IL-10 (Henry et al., 2009), causing an inhibition of IFN-γ 
production. Naundorf et al. (2009) reported this phenomenon of IL-10-
mediated IFN-γ inhibition, in which they demonstrated that in the presence of 
IL-10, IFN-γ produced by PBMCs was significantly reduced. IL-10 levels in the 
co-cultures should be tested in order to verify this hypothesis. 
 
Secondly, while levels of most cytokines were comparable upon blockade of 
CD137L, GM-CSF saw a drastic decrease in its production. This indicates 
that CD137-CD137L interaction is essential for the production of GM-CSF by 
T cells. GM-CSF has been shown to be crucial in the induction of EAE 
(Codarri et al., 2011). On another hand, Martinez Gomez et al. (2012) 
demonstrated that induction of EAE is dependent on CD137L signalling. 
Hence, our finding is the first to link these two reports, suggesting that 
CD137-CD137L interaction is needed for the production of GM-CSF, which is 
essential for the induction of EAE. 
 
4.6 CD137 remains undetected on human neurons and astrocytes 
CD137 has been elusive when it comes to protein expression in the human 
CNS. In spite of this, there are some studies that have reported CD137 
expression on human neurons and glial cells	   (Reali et al., 2003; Yun et al., 
2013; Blank et al., 2014). We attempted to verify these findings. However, we 
were unable to detect CD137 on hESC-derived dopaminergic neurons, 
astrocytic cell lines and primary human astrocytes despite various treatments 
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and conditions in vitro. The inability to detect CD137 protein on human CNS 
cells in vitro is similar to that of the murine system mentioned in Section 4.3. 
Conversely, we were able to observe CD137 expression on murine CNS 
tissues and this detectability of CD137 may apply for human brain tissue too. 
However, as expression of CD137 is activation-dependent (Schwarz et al., 
1995), a normal brain tissue may not express the protein (Wilcox et al., 2002). 
Therefore, for future experiments, brain tissues of patients with CNS diseases 
should be employed to increase chances of detecting CD137 protein on 
inflamed CNS-resident human cells. 
 
4.7 CD137-CD137L signalling in murine and human CNS do not mimic 
each other 
As GM-CSF production was dampened upon inhibition of CD137-CD137L 
interaction in the murine system, we seek to reproduce this finding in the 
human system. As GM-CSF is predominantly secreted by T cells, we ensured 
that CD137 on T cells was blocked by using anti-human CD137 antibody 
P2F2.  
 
To our surprise, this led to the enhancement of GM-CSF levels, instead of the 
reduction we observed in the murine system. GM-CSF was shown to be 
critical for the pathogenicity of TH17 cells, which is involved in autoimmunity	  
(El-Behi et al., 2011). As TH17 cells are primarily characterized by its IL-17 
secretion	   (Quesniaux et al., 2009), we also examined IL-17A levels. 
Interestingly, there was a decrease in IL-17A production. This effect of 
increased GM-CSF and decreased IL-17A productions could be due to 
CD137 signalling into T cells or the inhibition of CD137-CD137L interaction. 
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Hence, in order to determine the cause of this effect, we repeated the 
experiment but this time, the blockade directed towards CD137L. This was 
done by using anti-human CD137 antibodies. One of the antibody clones, 
P1A7, stood out as it showed the same trend of increased GM-CSF and 
decreased IL-17A secretions. All other treatments with various other anti-
human CD137L such as 5F4 and C65-485 saw comparable levels of IL-17A. 
As both treatments with anti-human CD137 and anti-human CD137L 
antibodies resulted in an increase in GM-CSF with a decrease in IL-17A, this 
indicates that the effect was brought about by the inhibition of CD137-CD137L 
interaction between T cells and U937.    
 
The transcription factor RORγt is the master regulator in TH17 cells and was 
reported to have a role in the production of GM-CSF	   (Codarri et al., 2011). 
However, the absence of enhanced RORγt expression upon CD137-CD137L 
interaction we observed proved otherwise. This suggests that GM-CSF 
expression may be driven by other transcription factors involved in other 
types of T helper cells such as TH1, which are known to express GM-CSF too 
(Shiomi & Usui, 2015). As RORγt is also responsible for the expression of IL-
17A	  (Ivanov et al., 2006), the lack of RORγt enhancement may be the reason 
for the lack of change in IL-17A levels when treated with 5F4 and C65-485. 
 
The opposite effect of GM-CSF and IL-17A levels is puzzling, considering that 
GM-CSF has been associated with the increase in TH17 cells pathogenicity in 
the murine system. However recently, Noster et al. (2014) demonstrated that, 
unlike in the murine system, GM-CSF and IL-17 are inversely regulated in the 
human T cells. This finding adds to the accumulating evidence in which 
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effects of CD137-CD137L interaction are subjected to species difference	  
(Baessler et al., 2010; Tang et al., 2011). It further emphasises the caution 
that has to be taken when translating findings in the murine system to the 
human system. 
4.8 Limitations of study 
There are a few caveats in this study, which need to be highlighted. Firstly, 
the use of calbindin-D28k in immunofluorescence studies was for the purpose 
of determining the identity of CD137-expressing CNS cells. This was based 
on the assumption that calbindin-D28k specifically stains for Purkinje cells in 
the CNS. However, there have been studies in which calbindin-D28k was 
detected on midbrain dopaminergic neurons and olfactory chemoreceptor 
neurons	   (Kishimoto et al., 1993; Liang et al., 1996). Now, this poses a 
problem if the component of CNS in which the tissue slices are derived from 
is not known. This could lead to the false identification of CD137-expressing 
CNS resident cells and potentially have an impact on future studies. 
 
Next, several cell lines were used in this study to replace primary cells as they 
allow for a stable source of a particular type of cell. However, cell lines usually 
do not provide results of similar value when compared to primary cells. This is 
due to the altered characteristics that the cell lines acquired upon 
immortalisation due to transformed transcriptomics	   (Pan et al., 2009). 
Furthermore, while cell lines provides the option of subculturing, this brings 
about the issue of genetic drift and hence, rendering the cell lines to become 
unreliable representation of the initial source (Hughes et al., 2007).  
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In this study, the monocytic cell line U937 was employed to replace human 
microglia. This was based on the assumption that as both are of myeloid 
origin, a monocytic cell line would give similar results as if a microglial cell line 
had been utilised. However, Ritzel et al. (2015) recently reported functional 
differences between the two types of cells under stress. The group 
demonstrated that microglia expresses higher ROS and has a different 
cytokine profile as compared to monocytes. This indicates that the use of 
monocytic cell line in place of microglia in in vitro studies may be unsuitable. 
 
Finally, numerous anti-CD137 and anti-CD137L antibodies employed in this 
study were assumed as blockades against CD137-CD137L interaction. 
However, this study has not taken into account the type of antibodies utilised, 
whether they were agonistic, antagonistic or neutralising antibodies. Each 
type of antibodies may bring out different effects to the same target cell. It 
would be best to determine the nature of the antibodies beforehand so that 
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5 CONCLUSION 
Much has yet to be unravelled about CD137 and its interaction with CD137L 
in the CNS. Currently, there are only a handful of publications that address 
the function of this signalling system in the CNS. This study has yielded a few 
unexpected findings and added valuable data to the current knowledge. 
 
In vivo studies done have provided first insights on the expression of murine 
CD137 on Purkinje cells. We have also demonstrated, for the first time, the 
enhancement of neuronal CD137 expression in diseased murine CNS. While 
the enhancement did not manifest itself in the number of cells expressing 
CD137, its portrayal was seen in the intensity of protein expression, indicating 
the specificity of murine CD137 expression in the CNS. Our study so far has 
not been able to detect CD137 in the human CNS. However, not all avenues 
have been explored and it is possible that the expression of CD137 in human 
CNS will be identified using new methods or tissues.  
 
Our in vitro findings revealed the intriguing observation of reduced CD137 
expression upon terminal differentiation of neurons. While the repercussions 
of this observation are still unclear, it points to the dedifferentiation of cells 
under pathological conditions, resulting in altered proteomics profile and 
hence, the upregulation of CD137 under said conditions.  
 
Aside from that, we uncovered a couple of mechanisms by which CD137L-
activated microglia is able to exert its effects on two different types of CD137-
expressing cells. Firstly, CD137L-activated microglia induces neuronal 
apoptosis. This done via the action of ROS secreted by activated microglia. 
	   84 
Secondly, CD137L-activated microglia establishes a pro-inflammatory milieu 
in the murine CNS by promoting T cell proliferation and the production of pro-
inflammatory cytokines such as GM-CSF, IFN-γ and MCP-1. However, what 
was observed in the murine system could not be reproduced in the human 
system. In fact, an opposite effect was observed in which GM-CSF was 
dampened upon cross-linkage of CD137. This corresponded with an increase 
in IL-17A but minimal changes were seen in levels of RORγt. 
 
As we seek to unravel the mechanisms behind CD137-CD137L interaction in 
the CNS, we need to keep in mind that results acquired from murine studies 
are not necessarily translatable to the human system. However, murine 
studies still provides invaluable insights and are necessary in order to build a 
solid basis for potential clinical studies in the future. Though this study has 
shed some light on the effects of CD137-CD137L interactions in microglia-
mediated immune responses in the murine system, there is still an immense 
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6 FUTURE WORK 
Our current data has shown that microglia-mediated immune responses 
driven by the CD137-CD137L signalling system may potentially play a crucial 
role in neuroinflammation. However, our findings have barely scratched the 
surface of this paradigm. Here, we highlight some of the gaps that still exist 
and questions that remain to be answered. 
 
It has been established that microglia can exist in two different states of 
activation, namely M1 and M2 phenotypes (Tang & Le, 2015). The M1 
phenotype has been classically associated with inflammation, characterised 
by the production of pro-inflammatory cytokines and ROS. On the other hand, 
the M2 phenotype has been reported to adopt an anti-inflammatory identity, 
which is involved in damage control and tissue reparation. Polarisation into a 
particular phenotype is dependent on the type of stimulus that the microglia 
receives (Cherry et al., 2014). We know that microglia is activated upon 
CD137L reverse signalling. However, we have yet to ascertain if CD137L 
reverse signalling renders the microglia to assume a M1 or M2 phenotype. 
While preliminary evidence from our studies shows that CD137L-activated 
microglia secrete ROS and some pro-inflammatory cytokines, it does not 
necessarily mean that they are M1 microglia. For all that is known, these 
CD137L-activated microglia may actually be of an intermediate phenotype or 
a totally different phenotype of its own. Hence, microglia activated by CD137L 
reverse signalling should be subjected to more thorough methods in order to 
determine its phenotype. This may have implications in the attempt to 
understand the role of CD137L-activated microglia in neuroinflammation as 
well as in determining future therapeutic directions. 
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Our study has demonstrated the expression of CD137 in murine CNS. 
However, this finding remains to be replicated in human CNS. While attempts 
have been made to detect CD137 expression on CNS primary cells as well as 
cell lines, it was to no avail. Blank et al. (2014) recently reported the 
expression of CD137 protein on reactive astrocytes in glioma tissues. Hence, 
future efforts to verify CD137 expression in human CNS should include 
staining of CNS tissues obtained from patients with CNS-related disease. 
 
Although microglia is the primary immune cell in the CNS, astrocytes have 
also been shown to be involved in neuroinflammation and several CNS-
related disorders	   (Minagar et al., 2002). In fact, astrocytes, present in the 
CNS milieu in close contact with microglia, are able to facilitate microglia 
activation	   (Shih et al., 2006). With the discovery of CD137 expression on 
astrocytes by Blank et al. (2014), there is a possibility that microglia may 
interact with astrocytes via CD137-CD137L signalling system. This could help 
to elucidate the complex crosstalk between microglia and astrocytes under 
normal as well as pathological conditions.  
 
Further studies could also be undertaken to explore the effect on CD137 and 
CD137L expressions upon differentiation. Yun et al. (2013) demonstrated that 
the neural stem cell line, C17.2, expresses CD137 and its ligand. However, 
when neuronal cell lines were tested, both CD137 and CD137L were 
undetectable	   (Schwarz et al., 1995). It suggests that differentiation may have 
an effect on the expression levels of CD137 and CD137L. This also implies 
that the CD137-CD137L signalling system may possibly play a role during 
early CNS development. On top of that, in diseases and disorders in which 
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dedifferentiation of cells occurs, CD137-CD137L interactions may perhaps be 
one of the mechanisms that drive the pathogenesis. 
 
Ultimately, we hope that the findings obtained in this study will be able to 
provide a basis to investigate potential contributions of CD137/CD137L 
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APPENDIX I BUFFERS AND SOLUTIONS 
RIPA buffer 
Component Quantity 
1 M Tris buffer (pH 7.4) 12.5 ml 
5 M sodium chloride (NaCl) 2.5 ml 
SDS (10% w/v) 2.5 ml 
Sodium deoxycholate (C24H39NaO4) 0.625 g 
Nonyl phenoxypolyethoxylethanol (NP-40) 2.5 ml 
Protease inhibitor (100×) 1× 
Distilled water Top up to 250 ml 
*Protease inhibitor was added prior to use. 
 
5× Laemmli sample buffer 
Component Quantity 
1 M Tris-HCl (pH 6.8) 2.5 ml 
SDS (10% w/v) 8 ml 
Glycerol 4 ml 
Bromophenol blue 4 mg 
β-mercaptoethanol 2 ml 
Distilled water Top up to 40 ml 
*β-mercaptoethanol was added prior to use. 
 
Western blot transfer buffer 
Component Quantity 
Tris 3.03 g 
Glycine 14.4 g 
Methanol 200 ml 
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10× PBS 
Component Quantity 
Sodium chloride (NaCl) 80 g 
Potassium chloride (KCl) 2 g 
Disodium hydrogen phosphate (Na2HPO4) 14.4 g 
Monopotassium phosphate (KH2PO4) 2.4 g 
Distilled water Top up to 1 L 




10× PBS 50 ml 
FBS 2.5 ml 
20% sodium azide (NaN3) 500 μl 
Distilled water Top up to 500 ml 
 
Resolving buffer (1 M Tris, pH 8.8) 
Component Quantity 
Tris 12.1 g 
Distilled water Top up to 100 ml 
*Adjusted to pH 8.8. 
 
Stacking buffer (1 M Tris, pH 6.8) 
Component Quantity 
Tris 12.1 g 
Distilled water Top up to 100 ml 
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APPENDIX II GELS 
12% SDS-PAGE gel 
Component Quantity 12% resolving gel 4% stacking gel 
SDS (10% w/v) 100 μl 40 μl 
Resolving buffer 3.75 ml - 
Stacking buffer - 500 μl 
30% acrylamide/bis solution 4 ml 667 μl 
TEMED 4 μl 4 μl 
10% ammonium persulfate (APS) 100 μl 40 μl 
Distilled water 2.05 ml 3.75 ml 
*TEMED and 10% APS were added prior to use. 
 
2% agarose gel with GelGreen™ 
Component Quantity 
Agarose 2 g  
GelGreen™ 5 μl 
Distilled water 100 ml 
*GelGreen™ was added prior to casting of gel. 
 
 
